Document_and_Entity_Informatio
Document and Entity Information Document (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Feb. 27, 2015 | Jun. 30, 2014 | |
Document Information [Line Items] | |||
Entity Registrant Name | NeoStem, Inc. | ||
Entity Central Index Key | 320017 | ||
Current Fiscal Year End Date | -19 | ||
Entity Filer Category | Accelerated Filer | ||
Document Type | 10-K | ||
Document Period End Date | 31-Dec-14 | ||
Document Fiscal Year Focus | 2014 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | FALSE | ||
Entity Common Stock, Shares Outstanding | 38,459,297 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Public Float | $200,360,650 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Current Assets | ||
Cash and cash equivalents | $19,174,061 | $46,133,759 |
Marketable Securities | 7,080,053 | 0 |
Accounts receivable trade, net of allowance for doubtful accounts of $385,362 and $391,829, respectively | 3,111,274 | 1,860,835 |
Deferred Costs | 2,566,989 | 1,270,223 |
Prepaids and other current assets | 4,349,167 | 1,561,933 |
Total current assets | 36,281,544 | 50,826,750 |
Property, plant and equipment, net | 15,960,731 | 12,844,216 |
Goodwill | 25,209,336 | 11,117,770 |
Intangible assets, net | 47,560,406 | 13,875,617 |
Other assets | 1,263,375 | 1,151,729 |
Assets, Total | 126,275,392 | 89,816,082 |
Current Liabilities | ||
Accounts payable | 5,661,173 | 3,354,908 |
Accrued liabilities | 4,322,901 | 4,018,026 |
Long-term Debt, Current Maturities | 1,109,612 | 0 |
Notes payable | 816,776 | 381,097 |
Mortgages payable | 0 | 213,112 |
Derivative Liabilities, Current | 0 | 23,175 |
Unearned revenues | 4,334,120 | 1,816,601 |
Total current liabilities | 16,244,582 | 9,806,919 |
Deferred income taxes | 18,176,190 | 4,379,226 |
Notes payable | 825,897 | 531,164 |
Long-term Debt | 0 | 3,023,609 |
Long-term Debt, Excluding Current Maturities | 13,890,388 | 0 |
Business Combination, Contingent Consideration, Liability | 18,260,000 | 9,450,000 |
Other long-term liabilities | 804,546 | 598,729 |
Total liabilities | 68,201,603 | 27,789,647 |
Commitments and Contingencies | ||
Stockholders' Equity | ||
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2014 and December 31, 2013 | 100 | 100 |
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 36,783,857 and 27,196,537 shares, at December 31, 2014 and December 31, 2013, respectively | 36,784 | 27,197 |
Additional paid-in capital | 350,428,903 | 299,594,525 |
Treasury stock, at cost | -705,742 | -705,742 |
Accumulated deficit | -291,246,538 | -236,373,605 |
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax | 1,329 | 0 |
Total NeoStem, Inc. stockholders' equity | 58,514,836 | 62,542,475 |
Noncontrolling interests | -441,047 | -516,040 |
Total equity | 58,073,789 | 62,026,435 |
Liabilities and Equity, Total | $126,275,392 | $89,816,082 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parentheticals) | 8-May-14 |
Common Stock, Shares, Issued | 5,329,593 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Revenues | $17,938,790 | $14,668,455 | $14,329,889 |
Cost of revenues | 15,678,475 | 12,947,217 | 11,949,124 |
Research and development | 29,194,262 | 16,917,396 | 10,451,070 |
Selling, general, and administrative | 30,806,807 | 21,612,793 | 22,315,346 |
Operating Expenses | 75,679,544 | 51,477,406 | 44,715,540 |
Operating loss | -57,740,754 | -36,808,951 | -30,385,651 |
Other income (expense): | |||
Other (expense) income, net | 2,926,003 | -1,614,858 | -4,314,228 |
Interest expense | -755,697 | -281,421 | -1,576,975 |
Nonoperating Income (Expense), Total | 2,170,306 | -1,896,279 | -5,891,203 |
Loss from operations before provision for income taxes and noncontrolling interests | -55,570,448 | -38,705,230 | -36,276,854 |
Income Tax Expense (Benefit) | -104,202 | 780,104 | -175,533 |
Net loss from continuing operations | -55,466,246 | -39,485,334 | -36,101,321 |
Loss on exit of segment | 0 | 0 | -30,267,990 |
Net loss | -55,466,246 | -39,485,334 | -66,369,311 |
Less - loss from continuing operations attributable to noncontrolling interests | -593,313 | -504,090 | -287,181 |
Less - loss from discontinued operations attributable to noncontrolling interests | 0 | 0 | -12,312,646 |
Net loss attributable to NeoStem, Inc. | -54,872,933 | -38,981,244 | -53,769,484 |
Warrant inducements | 0 | 0 | -1,012,819 |
Redeemable Preferred Stock Dividends | 0 | 0 | -528,023 |
Net Income (Loss) Available to Common Stockholders, Basic | -54,872,933 | -38,981,244 | -55,310,326 |
Amounts Attributable to NeoStem, Inc. common shareholders: | |||
Loss from continuing operations | -54,872,933 | -38,981,244 | -35,814,140 |
Loss from discontinued operations - net of taxes | 0 | 0 | -17,955,344 |
Net Income (Loss) Available to Common Stockholders, Basic | ($54,872,933) | ($38,981,244) | ($55,310,326) |
Basic and diluted (loss) per share attributable to: | |||
Continuing operations | ($1.68) | ($1.90) | ($2.59) |
Discontinued operations | $0 | $0 | ($1.30) |
NeoStem, Inc. common stockholders | ($1.68) | ($1.90) | ($4) |
Weighted average common shares outstanding | 32,756,102 | 20,495,771 | 13,841,997 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive income (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Net loss | ($55,466,246) | ($39,485,334) | ($66,369,311) |
Other comprehensive income (loss): | |||
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax | 1,329 | 0 | 0 |
Foreign currency translation elimination on exit of segment | 0 | 0 | -169,993 |
Foreign currency translation elimination on sale of segment | 0 | 0 | -4,387,371 |
Foreign currency translation | 0 | 0 | 405,021 |
Total other comprehensive income (loss) | 1,329 | 0 | -4,152,343 |
Comprehensive loss | -55,464,917 | -39,485,334 | -70,521,654 |
Noncontrolling interests elimination on sale of segment | 0 | 0 | -6,014,981 |
Comprehensive loss attributable to noncontrolling interests | -593,313 | -504,090 | -12,448,950 |
Comprehensive net loss attributable to NeoStem, Inc. common stockholders | ($54,871,604) | ($38,981,244) | ($52,057,723) |
Consolidated_Statements_of_Equ
Consolidated Statements of Equity (USD $) | Total | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Accumulated Deficit [Member] | Treasury Stock [Member] | Total NeoStem, Inc. Shareholders' Equity [Member] | Non-Controlling Interest in Subsidiary [Member] |
Beginning Balance at Dec. 31, 2011 | $80,132,518 | $100 | $10,933 | $200,957,035 | $4,152,343 | ($143,094,854) | $0 | $62,025,557 | $18,106,961 |
Beginning Balance (in shares) at Dec. 31, 2011 | 10,000 | 10,932,959 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | -66,369,311 | -53,769,484 | -53,769,484 | -12,599,827 | |||||
Foreign currency translation | 385,905 | 235,028 | 235,028 | 150,877 | |||||
Share-based compensation (in shares) | 336,427 | ||||||||
Share-based compensation | -6,712,536 | -336 | -6,712,200 | -6,712,536 | |||||
Proceeds from issuance of common stock (in shares) | 3,573,229 | ||||||||
Proceeds from issuance of common stock | 16,428,827 | 3,573 | 16,425,254 | 16,428,827 | |||||
Proceeds from exercise of options | 0 | ||||||||
Proceeds from warrant exercises (in shares) | 1,107,618.20 | ||||||||
Proceeds from warrant exercises | 6,604,419 | 1,108 | 6,603,311 | 6,604,419 | |||||
Repayment of Series E Preferred Principal and Dividends (in shares) | 279,237.50 | ||||||||
other comprehensive income, foreign currency translation elimination on sale of segment | -10,402,352 | 0 | -4,387,371 | -4,387,371 | -6,014,981 | ||||
Issuance Of Common Stock In Connection With Preferred Stock Settlement Value | 674,194 | 279 | 1,201,938 | 0 | 528,023 | 0 | 674,194 | ||
Warrant inducements | 145,895.20 | ||||||||
Stock Issued During Period, Value, Warrant Inducements | 228,676 | 146 | 228,822 | 228,676 | |||||
Stock Repurchased and Retired During Period, Value | 1,117,901 | 452,301 | 665,600 | 1,117,901 | |||||
Ending Balance at Dec. 31, 2012 | 32,820,159 | 100 | 16,375 | 231,218,615 | 0 | -197,392,361 | -665,600 | 33,177,129 | -356,970 |
Ending Balance (in shares) at Dec. 31, 2012 | 10,000 | 16,375,366 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | -39,485,334 | -38,981,244 | -38,981,244 | -504,090 | |||||
Share-based compensation (in shares) | 513,912 | ||||||||
Share-based compensation | -6,838,559 | -514 | -6,878,187 | -40,142 | -6,838,559 | ||||
Proceeds from issuance of common stock (in shares) | 9,712,724 | ||||||||
Proceeds from issuance of common stock | 58,736,166 | 9,713 | 58,726,453 | 58,736,166 | |||||
Proceeds from option exercises, shares | 31,369 | ||||||||
Proceeds from exercise of options | 150,658 | 31 | 150,627 | 150,658 | |||||
Proceeds from warrant exercises (in shares) | 563,167 | ||||||||
Proceeds from warrant exercises | 3,028,241 | 564 | 3,027,677 | 3,028,241 | |||||
Warrant inducements | 40,407 | 0 | |||||||
Stock Issued During Period, Value, Warrant Inducements | 62,014 | 0 | 62,014 | 62,014 | |||||
Change in Ownership in Subsidiary | 0 | -345,020 | -345,020 | 345,020 | |||||
Ending Balance at Dec. 31, 2013 | 62,026,435 | 100 | 27,197 | 299,594,525 | 0 | -236,373,605 | -705,742 | 62,542,475 | -516,040 |
Ending Balance (in shares) at Dec. 31, 2013 | 10,000 | 27,196,538 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | -55,466,246 | -54,872,933 | -54,872,933 | -593,313 | |||||
Marketable Securities, Unrealized Gain (Loss) | 1,329 | 1,329 | 1,329 | ||||||
Share-based compensation (in shares) | 916,359 | ||||||||
Share-based compensation | -11,209,542 | -916 | -11,208,626 | 0 | -11,209,542 | ||||
Proceeds from issuance of common stock (in shares) | 2,959,214 | ||||||||
Proceeds from issuance of common stock | 16,710,645 | 2,959 | 16,707,686 | 16,710,645 | |||||
Proceeds from option exercises, shares | 48,987 | ||||||||
Proceeds from exercise of options | 271,008 | 49 | 270,959 | 271,008 | |||||
Proceeds from warrant exercises (in shares) | 333,250 | ||||||||
Proceeds from warrant exercises | 1,720,725 | 333 | 1,720,392 | 1,720,725 | |||||
Stock Issued During Period, Shares, Acquisitions | 5,329,510 | ||||||||
Stock Issued During Period, Value, Acquisitions | 21,600,351 | 5,330 | 21,595,021 | 21,600,351 | |||||
Warrant inducements | 0 | ||||||||
Change in Ownership in Subsidiary | 0 | -668,306 | -668,306 | 668,306 | |||||
Ending Balance at Dec. 31, 2014 | $58,073,789 | $100 | $36,784 | $350,428,903 | $1,329 | ($291,246,538) | ($705,742) | $58,514,836 | ($441,047) |
Ending Balance (in shares) at Dec. 31, 2014 | 10,000 | 36,783,857 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Cash flows from operating activities: | |||
Net loss | ($55,466,246) | ($39,485,334) | ($66,369,311) |
Loss from discontinued operations | 0 | 0 | 30,267,990 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Common stock, stock options and warrants issued as payment for compensation, services rendered | 11,209,542 | 6,838,559 | 6,712,536 |
Depreciation and amortization | 2,186,949 | 1,605,608 | 1,550,571 |
Amortization of preferred stock discount and issuance cost | 0 | 0 | 1,609,495 |
Changes in fair value of derivative liability | -23,175 | -77,981 | -373,307 |
Changes in acquisition-related contingent consideration | -3,080,000 | 1,900,000 | 4,420,000 |
Loss on disposal of assets | 0 | 0 | 13,653 |
Bad debt (recovery) expense | -6,467 | -234,225 | 511,755 |
Deferred income taxes | -104,202 | 780,104 | -175,533 |
Amortization/Accretion on Marketable Securities | 51,517 | 0 | 0 |
Changes in operating assets and liabilities: | |||
Prepaid expenses and other current assets | -2,768,062 | -758,798 | -178,011 |
Accounts receivable | -1,198,844 | -573,005 | -554,884 |
Deferred costs | -1,296,766 | -157,198 | -465,280 |
Unearned revenues | 2,517,520 | 348,260 | 178,008 |
Other assets | 613,175 | -204,422 | 2,414,842 |
Accounts payable, accrued expenses and other liabilities | 469,821 | 2,916,739 | 1,677,551 |
Net cash used in operating activities - continuing operations | -46,895,238 | -27,101,693 | -18,759,925 |
Net cash provided by operating activities - discontinued operations | 0 | 0 | 4,907,407 |
Net cash used in operating activities | -46,895,238 | -27,101,693 | -13,852,518 |
Cash flows from investing activities: | |||
Cash Acquired from Acquisition | 50,894 | 0 | 0 |
Cash received in divestiture | 0 | 0 | 12,280,000 |
Payments to Acquire Marketable Securities | 8,043,241 | 0 | 0 |
Proceeds from Sale and Maturity of Marketable Securities | 913,000 | 0 | 0 |
Acquisition of property and equipment | 3,657,352 | 2,691,471 | 531,315 |
Net cash (used in) provided by investing activities - continuing operations | -10,736,699 | -2,691,471 | 11,748,685 |
Net cash used in investing activities - discontinued operations | 0 | 0 | -5,660,305 |
Net cash (used in) provided by investing activities | -10,736,699 | -2,691,471 | 6,088,380 |
Cash flows from financing activities: | |||
Proceeds from exercise of options | 271,008 | 150,658 | 0 |
Proceeds from exercise of warrants | 1,720,725 | 3,028,241 | 6,604,418 |
Net proceeds from issuance of capital stock | 16,710,645 | 58,736,165 | 16,428,827 |
Proceeds from long term debt | 15,000,000 | 0 | 0 |
Debt issuance costs | -523,830 | 0 | 0 |
Repayment of mortgage loan | 3,236,721 | 201,754 | 196,585 |
Proceeds from notes payable | 1,827,413 | 1,041,347 | 666,501 |
Repayment of notes payable | 1,097,001 | 503,172 | 440,477 |
Repayment of preferred stock | 0 | 0 | 5,394,263 |
Payment of dividend for preferred stock | 0 | 0 | 327,748 |
Payment for warrant inducement | 0 | 62,014 | 228,676 |
Net cash provided by financing activities - continuing operations | 30,672,239 | 62,189,471 | 17,111,997 |
Net cash used in provided by financing activities - discontinued operations | 0 | 0 | -8,370,228 |
Net cash provided by financing activities | 30,672,239 | 62,189,471 | 8,741,769 |
Impact of changes of foreign exchange rates | 0 | 0 | 14,389 |
Net (decrease) increase in cash and cash equivalents | -26,959,698 | 32,396,307 | 992,020 |
Cash and cash equivalents at beginning of year | 46,133,759 | 13,737,452 | 12,745,432 |
Cash and cash equivalents at end of year | 19,174,061 | 46,133,759 | 13,737,452 |
Cash paid during the period for: | |||
Interest | 232,500 | 274,100 | 1,771,800 |
Taxes | 0 | 0 | 2,100,000 |
Supplemental Schedule of non-cash investing activities: | |||
Capitalized interest | 0 | 0 | 182,000 |
Common stock, warrants and options received upon sale of Erye | 0 | 0 | 1,117,901 |
Supplemental schedule of non-cash financing activities | |||
Common stock and contingent consideration issued in merger | 33,490,351 | ||
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock | 0 | 0 | 1,026,600 |
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock | $0 | $0 | $175,700 |
The_Business
The Business | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
The Business [Abstract] | |||||
Nature of Operations [Text Block] | The Business | ||||
Overview | |||||
NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a vertically integrated, clinical-stage biopharmaceutical company that is pursuing the preservation and enhancement of human health through the development of cell based therapeutics that leverage the body’s natural ability to heal and fight disease. Our diversified pipeline and unique capabilities for innovative, cost-effective and efficient in-house development set us apart in this emerging industry as we work to fundamentally change the treatment paradigm for several serious diseases. | |||||
Our most advanced clinical program is based on our dendritic cell/cancer cell technology. It is focused on the development of an innovative cancer treatment that is designed to target the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (CSCs), using purified CSCs from a patient’s own tumor as an antigen source to induce or enhance an anti-tumor immune response in the patient. Our lead product candidate based on this platform technology, NBS20, targets malignant melanoma as an initial indication. NBS20 is being studied in patients with recurrent Stage III or Stage IV metastatic melanoma. The program has been granted Fast Track and Orphan designation by the Food and Drug Administration (FDA) and the protocol for the Phase 3 study, known as the Intus study, is the subject of a Special Protocol Assessment (SPA). Our SPA letter states that our Phase 3 clinical trial is adequately designed to provide the necessary data that, depending on outcome, could support a Biologics License Application (BLA) seeking marketing approval of NBS20. This protocol calls for randomizing 250 patients. Patient screening began in 1Q15 and randomization of the first patient is expected in 2Q15. Interim analysis of the data is targeted for 4Q2017. We are also evaluating other clinical indications for which we may advance this program, including lung, colon, ovarian and liver cancers. | |||||
Our company is also developing therapies that are designed to utilize CD34 cells to prevent heart failure and major adverse cardiac events following a severe heart attack, known as an ST-elevation myocardial infarction (STEMI), through the use of CD34 cells to regenerate tissue impacted by ischemia. Ischemia occurs when the supply of oxygenated blood in the body is restricted, causing tissue distress and death. We seek to improve oxygen delivery to tissues through the development and formation of new blood vessels. NBS10 is our most clinically advanced product candidate in our ischemic repair program. At the American Heart Association’s Scientific Sessions in November 2014, we reported data from the primary analysis of our 161 patient PreSERVE (acute myocardial infarction) AMI study. We are also planning the release of our one year data from the phase 2 trial on March 15, 2015 at the Annual Scientific Sessions of the American College of Cardiology. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing NBS10, a “personalized” adult stem cell product being developed for the treatment of patients with left ventricular dysfunction following a STEMI. The primary endpoints are measured by, (i) the change from baseline to six months in myocardial perfusion (RTSS) measured by an imaging technique (SPECT); and (ii) safety of bone marrow procurement and infusion as measured by occurrence of adverse events, serious adverse events (SAEs) and major adverse cardiac events (MACE). There are five secondary efficacy endpoints, two evaluating left ventricular ejection fraction, one evaluating MACE, and two evaluating quality of life. The reported data were based on all treated patients that had received six month follow-up for imaging. The median length follow up for mortality, adverse events, SAEs and MACE in these patients was twelve months. The reported results allowed for important observations about a potential dose-dependent treatment effect that will help guide the next phase of development. These observations about a potential dose dependent treatment effect were based on post hoc analyses of subsets of treated patients based on the number of cells they received. Notably, statistically significant dose-dependent increases in left ventricular function and decreases in serious adverse events were seen in patients who received the highest dose of cells (n patients), though no statistical significance was observed when NBS10 overall was compared to placebo on these measures. With respect to mortality, at one year there were no treatment group deaths while the control group saw a mortality rate of 3.6% (n=, equating to a statistically significant reduction in mortality. Regarding MACE, while more events occurred with NBS10 overall versus placebo, a non-significant trend toward fewer events was observed in patients who received higher doses of cells, with MACE occurring in 14% of placebo patients, 17% of patients who received less than 14 million cells, 10% of patients who received greater than 14 million cells and 7% of patients who received greater than 20 million cells. Finally, our hypothesis that SPECT used to measure perfusion could be used as a surrogate marker for the current medically relevant and regulatory endpoints was disproven, giving us valuable direction regarding endpoints and analyses for future clinical trials. We expect to complete the PreSERVE AMI study as defined through the final three-year follow-up and, in the meantime, plan to meet with the FDA to discuss our results and our proposal for the next step(s) in development. Finalization of the decision for next steps for NBS10 are expected in the second half of 2015. We also are evaluating other clinical indications that involve ischemia into which we may advance this program, including critical limb ischemia (CLI) and congestive heart failure (CHF). | |||||
Another platform technology we are developing is designed to utilize Regulatory T Cells (Tregs) to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease, it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues. We have received a letter from the FDA stating that we may proceed on a Phase 2 study of NBS03D, a Treg based therapeutic being developed to treat type 1 diabetes mellitus (T1DM) in adolescents, and we plan to initiate the trial in late 2015 or 2016 depending on resource availability. We are evaluating other clinical indications into which we may advance this program, including graft versus host disease, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), inflammatory bowel disease (IBD) and steroid resistant asthma. | |||||
Finally, we are actively exploring means by which we can take advantage of new regulations in Japan that permit conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy. Potential indications for this unique opportunity include our targeted cancer immunotherapy program in liver cancer and our ischemic repair program in CLI. | |||||
We believe that cell-based therapies have the potential to create a paradigm change in the treatment for a variety of diseases and conditions and we are evaluating other programs that we view as holding particular promise, including an aesthetics program for a topical skin application and a very small embryonic like (VSEL TM) stem cell program for the treatment of retinal degeneration, bone restoration and wound healing. | |||||
Through our wholly owned subsidiary, Progenitor Cell Therapy, LLC (PCT), we are recognized as a world industry leader in providing high quality innovative and reliable manufacturing capabilities and engineering solutions (e.g. process development) in the development of cell-based therapies. We operate three current Good Manufacturing Practice (cCGMP) facilities in Allendale, NJ, Mountain View, CA and Irvine, CA, respectively, and are poised to expand our facilities internationally. In addition to leveraging this core expertise in the development of our own products, we partner opportunistically with other industry leaders who recognize our unique ability to significantly improve their manufacturing processes and supply clinical and commercial material. | |||||
We look forward to further advancement of our cell based therapies to the market and to helping patients suffering from life-threatening medical conditions. Coupling our development expertise with our strong process development and manufacturing capability, we believe the stage is set for us to realize meaningful clinical development or our own proprietary platform technologies and manufacturing advancements, further positioning NeoStem to lead the cell therapy industry. | |||||
We anticipate requiring additional capital in order to fund the development of cell therapy product candidates and to grow the PCT business. To meet our short and long term liquidity needs, we currently expect to use existing cash, cash equivalents and marketable securities balances, our revenue generating activities, and a variety of other means, including the continued use of a common stock purchase agreement with Aspire Capital. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, additional warrant exercises, option exercises, partnerships and/or collaborations, and/or sale of assets. In addition, we will continue to seek as appropriate grants for scientific and clinical studies from various governmental agencies and foundations. We believe that our current cash, cash equivalents and marketable securities balances and revenue generating activities, along with access to funds under our agreement with Aspire Capital, will be sufficient to fund the business through the next 12 months. While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay or discontinue the acquisition and development of cell therapies, and/or the expansion of our business or raise funds on terms that we currently consider unfavorable. | |||||
Basis of Presentation | |||||
The accompanying Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) and include the accounts of the Company and its wholly owned and partially owned subsidiaries, the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 15), and the operations of our former Pharmaceutical Manufacturing - China segment through November 13, 2012, the date on which the segment was sold (see Note 15). These former segments are reported in discontinued operations. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, include all normal and recurring adjustments considered necessary to present fairly the Company's financial position as of December 31, 2014 and 2013, and the results of its operations and its cash flows for the years ended December 31, 2014, 2013, and 2012. | |||||
Use of Estimates | |||||
The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining the fair values of goodwill for potential goodwill impairments for our reporting units, fair values of In-Process R&D assets, fair values of acquisition-related contingent considerations, useful lives of our tangible and intangible assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions. | |||||
An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application. | |||||
Reclassifications | |||||
Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the year ended December 31, 2012 and 2013 to conform to the presentation for the year ended December 31, 2014. | |||||
Principles of Consolidation | |||||
The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below, as well as the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 15), and the operations of our former Pharmaceutical Manufacturing - China segment through November 13, 2012, the date which the segment was sold (see Note 15). These former segments are reported in discontinued operations. | |||||
Entity | Percentage of Ownership | Location | |||
NeoStem, Inc. | 100% | United States of America | |||
NeoStem Therapies, Inc. | 100% | United States of America | |||
Stem Cell Technologies, Inc. | 100% | United States of America | |||
Amorcyte, LLC | 100% | United States of America | |||
Progenitor Cell Therapy, LLC (PCT) | 100% | United States of America | |||
NeoStem Family Storage, LLC | 100% | United States of America | |||
Athelos Corporation (1) | 96.20% | United States of America | |||
PCT Allendale, LLC | 100% | United States of America | |||
NeoStem Oncology, LLC (2) | 100% | United States of America | |||
(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's (BD) initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of December 31, 2014, BD's ownership interest in Athelos was decreased to 3.8%, and our ownership increased to 96.2%. As a result in the change in ownership, approximately $0.7 million was transferred from additional paid in capital to non-controlling interests in 2014. | |||||
(2) On May 8, 2014, NeoStem acquired California Stem Cell, now known as NeoStem Oncology, LLC (see Note 3, Acquisition). Accordingly, the operating results of NeoStem Oncology, LLC prior to May 8, 2014 are not included in the Company's consolidated statements of operations and cash flows. |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 12 Months Ended | |
Dec. 31, 2014 | ||
Summary of Significant Accounting Policies [Abstract] | ||
Summary of Significant Accounting Policies [Text Block] | Summary of Significant Accounting Policies | |
Cash and Cash Equivalents | ||
Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. | ||
Concentration of Risks | ||
We are subject to credit risk from our portfolio of cash and cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. | ||
We are also subject to credit risk from our accounts receivable related to our services. The majority of our trade accounts receivable arises from services in the United States. | ||
For the year ended December 31, 2014, four customers represented 16%, 11%, 11%, and 10% respectively, of total revenues recognized. As of December 31, 2014, four customers represented 68% of our accounts receivable. | ||
Marketable Securities | ||
The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline. | ||
Accounts Receivable | ||
Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk. | ||
Deferred Costs | ||
The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's deferred costs represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market. | ||
Property, Plant, and Equipment | ||
The cost of property, plant and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property, plant and equipment are as follows: | ||
Building and improvements | 25-30 years | |
Machinery and equipment | 8-12 years | |
Lab equipment | 5-7 years | |
Furniture and fixtures | 5-12 years | |
Software | 3-5 years | |
Leasehold improvements | Life of lease | |
Goodwill and Indefinite-Lived Intangible Assets | ||
Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development (IPR&D) for NBS10, the clinical candidate acquired in the Amorcyte acquisition, as the Company expects this research and development to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. | ||
The Company reviews goodwill and indefinite-lived intangible assets at least annually, or at the time a triggering event is identified for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the IPR&D below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing an income approach model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s and IPR&D's estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with its accounting policy, the Company tested goodwill for impairment as of December 31, 2014, 2013, and 2012 for its two reporting units as well as its IPR&D, and concluded there was no goodwill and IPR&D impairment. | ||
Definite-lived Intangible Assets | ||
Definite-lived intangible assets consist of customer lists, manufacturing technology, tradenames, patents and rights. These intangible assets are amortized on a straight line basis over their respective useful lives. The Company reviews definite-lived intangibles assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No events were noted in 2014, 2013, and 2012. | ||
Recognizing and Measuring Assets Acquired and Liabilities Assumed in Business Combinations at Fair Value | ||
The Company accounts for acquired businesses using the purchase method of accounting, which requires that assets acquired and liabilities assumed be recorded at date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to IPR&D are included on the balance sheet . Intangible assets, including IPR&D assets upon successful completion of the project and approval of the product, are amortized on a straight-line basis to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected from future net cash flow streams, the timing of approvals for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the resulting timing and amount charged to, or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results. | ||
The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates, post-tax gross profit levels and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The resulting probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value at that time and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Changes in assumptions utilized in our contingent consideration fair value estimates could result in an increase or decrease in our contingent consideration obligation and a corresponding charge to operating loss or gain. | ||
Share-Based Compensation | ||
The Company expenses all share-based payment awards to employees, directors, consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant. | ||
Loss Per Share | ||
Basic loss per share is based on the weighted effect of all common shares issued and outstanding, and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share, which is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive in all periods presented due to losses incurred. | ||
Derivatives | ||
Derivative instruments, including derivative instruments embedded in other contracts, are recorded on the balance sheet as either an asset or liability measured at its fair value. Changes in the fair value of derivative instruments are recognized currently in results of operations unless specific hedge accounting criteria are met. The Company has not entered into hedging activities to date. Changes in the derivative value are recorded as other income (expense) on the consolidated statements of operations. | ||
Income Taxes | ||
The Company recognizes (a) the amount of taxes payable or refundable for the current year and (b) deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The Company continues to evaluate the accounting for uncertainty in tax positions at the end of each reporting period. The guidance requires companies to recognize in their financial statements the impact of a tax position if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The position ascertained inherently requires judgment and estimates by management. The Company recognizes interest and penalties as a component of income tax expense. | ||
Foreign Currency Translation | ||
Results of the Company’s former Chinese operating segments were translated at the average exchange rates during the period, and assets and liabilities were translated at the closing rate at the end of each reporting period. Cash flows were also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows did not necessarily agree with changes in the corresponding balances on the consolidated balance sheet. | ||
Treasury Stock | ||
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital. | ||
Revenue Recognition | ||
Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts. | ||
We recognize revenues when all of the following conditions are met: | ||
• | persuasive evidence of an arrangement exists; | |
• | delivery has occurred or the services have been rendered; | |
• | the fee is fixed or determinable; and | |
• | collectability is probable. | |
The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform. | ||
Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. Progress billings collected prior to contract completion are recorded as unearned revenue until such time the contract is completed, which usually requires formal client acceptance. | ||
Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met. | ||
Some client agreements include multiple elements, comprised of cell process development and cell manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price. | ||
Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the years ended December 31, 2014, 2013, and 2012, clinical services reimbursements were $3.7 million, $2.1 million, and $3.5 million, respectively. | ||
Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments. | ||
Research and Development Costs | ||
Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred. | ||
To further drive the Company’s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned. | ||
New Accounting Pronouncement | ||
In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2016 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements. | ||
In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements - Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the provisions in this ASU should be followed to determine whether to disclose information about the relevant conditions and events. The ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the adoption of this ASU and its impact on the consolidated financial statements. |
Acquisitions_Acquisitions_Note
Acquisitions Acquisitions (Notes) | 12 Months Ended | |||||||||||||||
Dec. 31, 2014 | ||||||||||||||||
Identified Assets Acquired [Abstract] | ||||||||||||||||
Mergers, Acquisitions and Dispositions Disclosures [Text Block] | Acquisition | |||||||||||||||
On May 8, 2014, NeoStem closed (the “Closing”) its acquisition of CSC (the “CSC Acquisition”), pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among NeoStem and its acquisition subsidiaries (collectively, "Subco"), CSC, and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”). At Closing, Fortis Advisors LLC succeeded to the duties of the CSC Representative pursuant to the Merger Agreement. Pursuant to the Merger Agreement, on the Closing Date, Subco was merged with CSC (the “Merger”), with Subco surviving the Merger as a wholly-owned subsidiary of NeoStem. At Closing, Subco changed its legal name to NeoStem Oncology, LLC. | ||||||||||||||||
Aggregate Merger Consideration | ||||||||||||||||
Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (CSC Common Stock) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (CSC Options) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock): | ||||||||||||||||
(1)An aggregate of 5,329,593 shares of NeoStem common stock (subject to payment of nominal cash in lieu of fractional shares) (the “Closing Merger Consideration”). | ||||||||||||||||
(2)if payable after the Closing, certain payments in an amount of up to $90 million in the aggregate, payable in shares of NeoStem Common Stock or cash, in NeoStem’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC business being acquired by NeoStem (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”). | ||||||||||||||||
The fair value of the net assets acquired in the CSC Acquisition was $19.4 million. The fair value of the Merger Consideration paid by NeoStem was valued at $33.5 million, resulting in the recognition of goodwill in the amount of $14.1 million. The consideration paid was comprised of equity issued and milestone payments. The fair value of the equity issued by NeoStem was valued at $21.6 million. The fair value of the milestone payments was valued at $11.9 million, and is contingent on the achievement of certain milestones associated with the future development of the acquired programs. Such contingent consideration has been classified as a liability and will be subject to remeasurement at the end of each reporting period. | ||||||||||||||||
The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands): | ||||||||||||||||
Cash and cash equivalents | $ | 51 | ||||||||||||||
Accounts receivable trade, net | 45 | |||||||||||||||
Prepaids and other current assets | 19 | |||||||||||||||
Property, plant and equipment, net | 1,041 | |||||||||||||||
Other assets | 201 | |||||||||||||||
Goodwill | 14,092 | |||||||||||||||
In-Process R&D | 34,290 | |||||||||||||||
Accounts payable | (333 | ) | ||||||||||||||
Accrued liabilities | (2,014 | ) | ||||||||||||||
Deferred tax liability | (13,901 | ) | ||||||||||||||
$ | 33,491 | |||||||||||||||
The total cost of the acquisition, which is still preliminary, has been allocated to the assets acquired and the liabilities assumed based on their estimated fair values at the date of the acquisition. The final allocation is expected to be completed during the measurement period which is one year from the date of acquisition. For the period since the CSC Acquisition (May 9, 2014 to December 31, 2014), NeoStem recorded $0.04 million in revenues and a net loss of approximately $7.6 million attributable to CSC. | ||||||||||||||||
Pro Forma Financial Information (unaudited) | ||||||||||||||||
The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the acquisition of CSC had occurred on January 1, 2013 (in thousands, except per share amounts): | ||||||||||||||||
Twelve Months Ended December 31, 2014 | Twelve Months Ended December 31, 2013 | |||||||||||||||
(As Reported) | (Proforma -Unaudited) | (As Reported) | (Proforma -Unaudited) | |||||||||||||
Revenues | $ | 17,939 | $ | 18,649 | $ | 14,668 | $ | 15,471 | ||||||||
Net loss | $ | (55,467 | ) | $ | (57,964 | ) | $ | (39,485 | ) | $ | (44,790 | ) | ||||
Net loss attributable to NeoStem | $ | (54,873 | ) | $ | (57,371 | ) | $ | (38,981 | ) | $ | (44,286 | ) | ||||
Net loss per share attributable to NeoStem | $ | (1.68 | ) | $ | (1.51 | ) | $ | (1.90 | ) | $ | (1.71 | ) | ||||
The unaudited supplemental pro forma financial information should not be considered indicative of the results that would have occurred if the acquisition of CSC had been consummated on January 1, 2013, nor are they indicative of future results. |
AvailabeforSaleSecurities_Avai
Availabe-for-Sale-Securities Available-for-Sale-Securities (Notes) | 12 Months Ended | |||||||||||||||
Dec. 31, 2014 | ||||||||||||||||
Available-for-sale Securities [Abstract] | ||||||||||||||||
Cash, Cash Equivalents, and Marketable Securities [Text Block] | Available-for-Sale-Securities | |||||||||||||||
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands): | ||||||||||||||||
December 31, 2014 | ||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | |||||||||||||
Certificate of deposits | $ | 249 | $ | — | $ | — | $ | 249 | ||||||||
Money market funds | 12,791.90 | — | — | 12,791.90 | ||||||||||||
Municipal debt securities | 9,317.30 | 1.3 | — | 9,318.60 | ||||||||||||
Total | $ | 22,358.20 | $ | 1.3 | $ | — | $ | 22,359.50 | ||||||||
Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands): | ||||||||||||||||
December 31, 2014 | ||||||||||||||||
Cash and cash equivalents | $ | 15,279.40 | ||||||||||||||
Marketable securities | 7,080.10 | |||||||||||||||
Total | $ | 22,359.50 | ||||||||||||||
The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands): | ||||||||||||||||
December 31, 2014 | ||||||||||||||||
Amortized Cost | Estimated Fair Value | |||||||||||||||
Less than one year | $ | 22,358.20 | $ | 22,359.50 | ||||||||||||
Greater than one year | — | — | ||||||||||||||
Total | $ | 22,358.20 | $ | 22,359.50 | ||||||||||||
Deferred_Costs
Deferred Costs | 12 Months Ended |
Dec. 31, 2014 | |
Inventories [Abstract] | |
Inventory Disclosure [Text Block] | Deferred Costs |
Deferred costs representing work in process for costs incurred on process development contracts that have not been completed, were $2.6 million and $1.3 million as of December 31, 2014 and December 31, 2013, respectively. The Company also has deferred revenue of approximately $3.9 million and $1.5 million of progress billings received as of December 31, 2014 and December 31, 2013, respectively, related to these contracts. |
Property_Plant_Equipment
Property, Plant & Equipment | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Property, Plant and Equipment [Abstract] | |||||||||
Property, Plant and Equipment Disclosure [Text Block] | Property, Plant and Equipment | ||||||||
Property, plant, and equipment consisted of the following (in thousands): | |||||||||
December 31, | |||||||||
2014 | 2013 | ||||||||
Building and improvements | $ | 11,298.70 | $ | 11,229.90 | |||||
Machinery and equipment | 68.3 | 58.2 | |||||||
Lab equipment | 6,324.70 | 2,743.70 | |||||||
Furniture and fixtures | 1,166.30 | 958 | |||||||
Software | 312.4 | 203.1 | |||||||
Leasehold improvements | 2,219.60 | 674.1 | |||||||
Property, plant and equipment, gross | 21,390.00 | 15,867.00 | |||||||
Accumulated depreciation | (5,429.3 | ) | (3,022.8 | ) | |||||
Property, plant and equipment, net | $ | 15,960.70 | $ | 12,844.20 | |||||
The Company’s results included depreciation expense of approximately $1.6 million, $1.0 million and $1.0 million for the years ended December 31, 2014, 2013, and 2012, respectively. |
Loss_Per_Share
Loss Per Share | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Loss Per Share [Abstract] | |||||||||
Loss Per Share [Text Block] | Loss Per Share | ||||||||
For the years ended December 31, 2014, 2013, and 2012 the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive in the periods presented. At December 31, 2014, 2013, and 2012 the Company excluded the following potentially dilutive securities: | |||||||||
December 31, | |||||||||
2014 | 2013 | 2012 | |||||||
Stock Options | 4,427,276 | 2,932,191 | 2,168,668 | ||||||
Warrants | 3,550,956 | 4,898,266 | 5,528,761 | ||||||
Restricted Shares | 280,481 | 78,500 | 34,250 | ||||||
ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block] | At December 31, 2014, 2013, and 2012 the Company excluded the following potentially dilutive securities: | ||||||||
December 31, | |||||||||
2014 | 2013 | 2012 | |||||||
Stock Options | 4,427,276 | 2,932,191 | 2,168,668 | ||||||
Warrants | 3,550,956 | 4,898,266 | 5,528,761 | ||||||
Restricted Shares | 280,481 | 78,500 | 34,250 | ||||||
Fair_Value_Measurements
Fair Value Measurements | 12 Months Ended | ||||||||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||||||||
Fair Value Measurements [Abstract] | |||||||||||||||||||||||||||||||||
Fair Value Measurements [Text Block] | Fair Value Measurements | ||||||||||||||||||||||||||||||||
Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories: | |||||||||||||||||||||||||||||||||
Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. | |||||||||||||||||||||||||||||||||
Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. | |||||||||||||||||||||||||||||||||
Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. | |||||||||||||||||||||||||||||||||
The Company classifies the fair value of the warrant derivative liabilities as level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. In May 2014, the warrants expired and the value of the warrant derivative liabilities were written off and recorded in other expenses in our consolidated statement of operations. | |||||||||||||||||||||||||||||||||
The Company classifies the fair value of contingent consideration obligations as level 3 inputs. The Company has recognized contingent consideration obligations related to the following: | |||||||||||||||||||||||||||||||||
• | In October 2011, in connection with the Company's acquisition of Amorcyte, contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate NBS10 (in the event of and following the date of first commercial sale of NBS10), provided that in the event NeoStem sublicenses NBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). The contingent consideration fair value decreased from $9.5 million as of December 31, 2013 to $5.5 million as of December 31, 2014. The change in estimated fair value is based primarily on the Company's updates to the discounted cash flow model using a probability-weighted income approach subsequent to the reporting of the primary analysis from the Preserve AMI Phase 2 clinical trial in the fourth quarter of 2014, and has been recorded in other expenses in our consolidated statement of operations. | ||||||||||||||||||||||||||||||||
• | In May 2014, in connection with the Company's acquisition of CSC, contingent consideration obligations were recognized relating to milestone payments of up to $90 million, based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value recognized in the acquisition in May 2014 was $11.9 million. The contingent consideration fair value increased to $12.8 million as of December 31, 2014. The change in estimated fair value is based on changes in assumptions regarding the timing of certain milestone achievements, as well as the time progression to reach those milestones as of December 31, 2014, and has been recorded in other expenses in our consolidated statement of operations. | ||||||||||||||||||||||||||||||||
The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. | |||||||||||||||||||||||||||||||||
The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2014, and December 31, 2013 (in thousands): | |||||||||||||||||||||||||||||||||
December 31, 2014 | December 31, 2013 | ||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||
Assets: | |||||||||||||||||||||||||||||||||
Marketable securities - available for sale | $ | — | $ | 7,080.00 | $ | — | $ | 7,080.00 | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||
$ | — | $ | 7,080.00 | $ | — | $ | 7,080.00 | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||
Liabilities: | |||||||||||||||||||||||||||||||||
Warrant derivative liabilities | — | — | — | — | — | — | 23.2 | 23.2 | |||||||||||||||||||||||||
Contingent consideration | — | — | 18,260.00 | 18,260.00 | — | — | 9,450.00 | 9,450.00 | |||||||||||||||||||||||||
$ | — | $ | — | $ | 18,260.00 | $ | 18,260.00 | $ | — | $ | — | $ | 9,473.20 | $ | 9,473.20 | ||||||||||||||||||
There were no transfers of financial instruments to or from Levels 1, 2 or 3 during the periods presented. For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2014 by type of instrument (in thousands): | |||||||||||||||||||||||||||||||||
Year Ended | |||||||||||||||||||||||||||||||||
December 31, 2014 | |||||||||||||||||||||||||||||||||
Warrants | Contingent Consideration | Total | |||||||||||||||||||||||||||||||
Beginning liability balance | $ | 23.2 | $ | 9,450.00 | $ | 9,473.20 | |||||||||||||||||||||||||||
Amount issued in acquisition | — | 11,890.00 | 11,890.00 | ||||||||||||||||||||||||||||||
Change in fair value recorded in operations | — | (3,080.0 | ) | (3,080.0 | ) | ||||||||||||||||||||||||||||
Expiration | (23.2 | ) | — | (23.2 | ) | ||||||||||||||||||||||||||||
Ending liability balance | $ | — | $ | 18,260.00 | $ | 18,260.00 | |||||||||||||||||||||||||||
Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, and accounts payable. |
Goodwill_and_Other_Intangible_
Goodwill and Other Intangible Assets | 12 Months Ended | |||||||||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||||||||
Goodwill and Other Intangible Assets [Abstract] | ||||||||||||||||||||||||||
Goodwill and Intangible Assets [Text Block] | Goodwill and Other Intangible Assets | |||||||||||||||||||||||||
The following table summarizes the changes in the carrying amount of goodwill (in thousands): | ||||||||||||||||||||||||||
Total | ||||||||||||||||||||||||||
Balance as of December 31, 2013 | $ | 11,117.80 | ||||||||||||||||||||||||
Goodwill resulting from the acquisition of CSC | 14,091.50 | |||||||||||||||||||||||||
Balance as of December 31, 2014 | $ | 25,209.30 | ||||||||||||||||||||||||
The Company's intangible assets and related accumulated amortization as of December 31, 2014 and December 31, 2013 consisted of the following (in thousands): | ||||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | |||||||||||||||||||||||||
Useful Life | Gross | Accumulated Amortization | Net | Gross | Accumulated Amortization | Net | ||||||||||||||||||||
Customer list | 10 years | $ | 1,000.00 | $ | (395.1 | ) | $ | 604.9 | $ | 1,000.00 | $ | (295.1 | ) | $ | 704.9 | |||||||||||
Manufacturing technology | 10 years | 3,900.00 | (1,540.9 | ) | 2,359.10 | 3,900.00 | (1,150.9 | ) | 2,749.10 | |||||||||||||||||
Tradename | 10 years | 800 | (316.1 | ) | 483.9 | 800 | (236.1 | ) | 563.9 | |||||||||||||||||
In process R&D | Indefinite | 43,690.00 | — | 43,690.00 | 9,400.00 | — | 9,400.00 | |||||||||||||||||||
Patent rights | 19 years | 669 | (246.5 | ) | 422.5 | 669 | (211.3 | ) | 457.7 | |||||||||||||||||
Total Intangible Assets | $ | 50,059.00 | $ | (2,498.6 | ) | $ | 47,560.40 | $ | 15,769.00 | $ | (1,893.4 | ) | $ | 13,875.60 | ||||||||||||
Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands): | ||||||||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||||||||
Cost of revenue | $ | 316.8 | $ | 390 | $ | 390 | ||||||||||||||||||||
Research and development | 108.4 | 35.2 | 35.2 | |||||||||||||||||||||||
Selling, general and administrative | 180 | 180 | 180 | |||||||||||||||||||||||
Total | $ | 605.2 | $ | 605.2 | $ | 605.2 | ||||||||||||||||||||
Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands): | ||||||||||||||||||||||||||
2015 | $ | 605.2 | ||||||||||||||||||||||||
2016 | 605.2 | |||||||||||||||||||||||||
2017 | 605.2 | |||||||||||||||||||||||||
2018 | 605.2 | |||||||||||||||||||||||||
2019 | 605.2 | |||||||||||||||||||||||||
Thereafter | 44,534.40 | |||||||||||||||||||||||||
$ | 47,560.40 | |||||||||||||||||||||||||
Accrued_Liabilities
Accrued Liabilities | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Accrued Liabilities [Abstract] | ||||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Accrued Liabilities | |||||||
Accrued liabilities were as follow (in thousands): | ||||||||
December 31, | ||||||||
2014 | 2013 | |||||||
Salaries, employee benefits and related taxes | $ | 2,807.20 | $ | 2,325.80 | ||||
Professional fees | 495.4 | 544.8 | ||||||
License fees | — | 500 | ||||||
Other | 1,020.30 | 647.4 | ||||||
$ | 4,322.90 | $ | 4,018.00 | |||||
Debt
Debt | 12 Months Ended | |||
Dec. 31, 2014 | ||||
Debt [Abstract] | ||||
Debt Disclosure [Text Block] | Debt | |||
Notes Payable | ||||
As of December 31, 2014 and December 31, 2013, the Company had notes payable of approximately $1.6 million and $0.9 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years. | ||||
Long-Term Debt | ||||
On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender has agreed to lend the Company up to $20.0 million. Upon entering into the Loan and Security Agreement, the Lender disbursed $15.0 million (“Term Loan A”). Under the terms of the Loan and Security Agreement, during the Second Draw Period (as defined below), the Company may, subject to certain conditions, borrow from Lender an additional $5.0 million (“Term Loan B”, together with Term Loan A, the “Term Loans”). The “Second Draw Period” is the period of time: (a) commencing on the date that Lender receives evidence in a form and substance satisfactory to Lender that the Company has entered into a strategic arrangement with respect to the Company’s NBS10 product candidate for ST Elevation Myocardial Infarction and receives an upfront payment of not less than $10.0 million in connection therewith, and (b) ending on the earlier of September 19, 2015 or the occurrence of an event of default under the Term Loans. After repayment of all outstanding amounts due under two loans from TD Bank, N.A. in the amount of approximately $3.1 million, and deductions for debt offering/issuance costs and interim period interest, the net proceeds from Term Loan A were $11.3 million. The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The proceeds from the Term Loans may be used to satisfy the Company’s future working capital needs, including the development of its cell therapy product candidates. | ||||
The Company will make interest only payments on the outstanding amount of Term Loans on a monthly basis until October 1, 2015 at a rate of 8.50% per annum; provided however, such interest-only period may be extended to April 1, 2016, in the event of either (1) the signing of a partnership for (x) traumatic brain injury indication for the Company's Ischemic Repair Program or for its VSELTM Program or (y) critical limb ischemia indication for its Ischemic Repair Program; or (2) the initiation of the Intus Phase 3 study evaluating the Company's product candidate NBS20 (also referred to as DC/TC) in patients with Stage IV or recurrent Stage III metastatic melanoma. Commencing on the date that principal payments commence, the Company will make consecutive monthly payments of principal and interest based upon a repayment schedule equal to (a) 36 months, if the Term Loans begin amortizing on October 1, 2015, or (b) 30 months, if the Term Loans begin amortizing on April 1, 2016. The Term Loans mature on September 1, 2018. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest), subject to a prepayment fee that is determined based on the date the loan is prepaid. The Company is also required to pay Lender a final payment fee equal to 8% of the Term Loan A and Term Loan B (if disbursed). The final payment fee will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The Company paid a facility fee in the amount of $100,000 in connection with Term Loan A. | ||||
Under the Loan and Security Agreement and a related mortgage, the Company granted to Lender a security interest in all of the Company’s real property and personal property now owned or hereafter acquired, excluding intellectual property, and certain other assets and exemptions. The Company also entered into a Mortgage and Absolute Assignment of Leases and Rents (the "Mortgage"). The Company also granted Lender a security interest in the shares of the Company’s subsidiaries. The Loan and Security Agreement restricts the ability of the Company to: (a) convey, lease, sell, transfer or otherwise dispose of any part of its business or property; and (b) incur any additional indebtedness. The Loan and Security Agreement provides for standard indemnification of Lender and contains representations, warranties and certain covenants of the Company. Upon the occurrence of an event of default by the Company under the Loan and Security Agreement, Lender will have customary acceleration, collection and foreclosure remedies. There are no financial covenants associated with the Loan and Security Agreement. As of December 31, 2014, the Company was in compliance with all covenants under the Loan and Security Agreement. | ||||
Estimated future principal payments, interest, and fees due under the Loan and Security Agreement are as follows: | ||||
Years Ending December 31, | (in millions) | |||
2015 | $ | 2.4 | ||
2016 | 5.7 | |||
2017 | 5.7 | |||
2018 | 5.4 | |||
Total | $ | 19.2 | ||
During the year ended December 31, 2014, the Company recognized $0.3 million of interest expense related to the Loan and Security Agreement. | ||||
Mortgages Payable | ||||
In October 2007, PCT issued a note to borrow $3.1 million (the “First Mortgage”) in connection with its $3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”). The First Mortgage was payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The monthly installment was $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments were subject to adjustment on October 1, 2017. The outstanding balance was approximately $2.5 million at December 31, 2013. In connection with the Loan and Security Agreement signed in September 2014, the remaining mortgage obligation was repaid, along with accrued interest and mortgage termination fees. | ||||
In December 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1 million (the "Second Mortgage") on the Allendale Property with TD Bank, N.A. The initial guarantors of the Second Mortgage were PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Regional Cancer Care Associates LLC and certain of its partners. The Second Mortgage was for124 months at a fixed rate of 6% for the first 64 months. The outstanding balance was approximately $0.8 million at December 31, 2013. In connection with the Loan and Security Agreement signed in September 2014, the remaining mortgage obligation was repaid, along with accrued interest and mortgage termination fees. | ||||
Prior to the full repayment of the mortgages in September 2014, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. in December 2013, whereby prior guarantors were released (see Note 16) and replaced with NeoStem, PCT, and NeoStem Family Storage, LLC. |
Shareholders_Equity
Shareholders' Equity | 12 Months Ended | |||||||||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||||||||
Shareholdersb Equity [Abstract] | ||||||||||||||||||||||||||
Stockholders' Equity Note Disclosure [Text Block] | Stockholders' Equity | |||||||||||||||||||||||||
Reverse Stock Split | ||||||||||||||||||||||||||
On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “Additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split. | ||||||||||||||||||||||||||
Equity Plans | ||||||||||||||||||||||||||
The Company's 2003 Equity Participation Plan (the “2003 Equity Plan”) expired in 2013 and accordingly, equity awards under the 2003 Equity Plan can no longer be issued. The Company's 2009 Equity Compensation Plan (the “2009 Equity Plan”) makes up to 8,995,000 shares of common stock of the Company (as of December 31, 2014) available for issuance to employees, consultants, advisors and directors of the Company and its subsidiaries pursuant to incentive or non-statutory stock options, restricted and unrestricted stock awards and stock appreciation rights. | ||||||||||||||||||||||||||
All stock options under the 2003 Equity Plan were granted and the 2009 Equity Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a consultant, employee or director of the Company. | ||||||||||||||||||||||||||
The 2009 Equity Plan was originally adopted by the stockholders of the Company on May 8, 2009. On October 29, 2009, the stockholders of the Company approved an amendment to the 2009 Equity Plan to increase the number of shares of common stock available for issuance thereunder from 380,000 to 975,000. At the 2010 Annual Meeting of Stockholders of the Company held on June 2, 2010, the stockholders approved an amendment to increase this number to 1,375,000. At a Special Meeting of Stockholders of the Company held on January 18, 2011, the stockholders approved an amendment to increase this number to 1,775,000. At the 2011 Annual Meeting of Stockholders of the Company held on October 14, 2011, the stockholders approved an amendment to increase this number to 2,375,000. At the 2012 Annual Meeting of Stockholders of the Company held on October 5, 2012, the stockholders approved an amendment to (i) merge the 570,000 shares reserved for issuance under the Company's 2009 Non-U.S. Based Equity Compensation Plan (the "Non-U.S. Plan") with and into the 2009 Equity Plan, and (ii) increase by 450,000 the aggregate number of shares authorized for issuance under the 2009 Equity Plan (the “2009 Amended & Restated Equity Plan”). At the Company's 2013 Annual Meeting held October 3, 2013, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance to 5,995,000. At the Company's 2014 Annual Meeting held October 6, 2014, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance to 8,995,000. | ||||||||||||||||||||||||||
The number of remaining shares authorized to be issued under the various equity plans are as follows: | ||||||||||||||||||||||||||
2003 Equity Plan | 2009 Equity Plan | |||||||||||||||||||||||||
Shares Authorized for Issuance | 250,000 | 8,995,000 | ||||||||||||||||||||||||
Outstanding Stock Options | (122,395 | ) | (4,304,881 | ) | ||||||||||||||||||||||
Exercised Stock Options | (9,250 | ) | (80,856 | ) | ||||||||||||||||||||||
Restricted stock or equity grants issued under Equity Plans | (88,993 | ) | (946,711 | ) | ||||||||||||||||||||||
Shares Expired | (29,362 | ) | — | |||||||||||||||||||||||
Total common shares remaining to be issued under the Equity Plans | — | 3,662,552 | ||||||||||||||||||||||||
The Company adopted an employee stock purchase plan effective January 1, 2013, and authorized 500,000 shares under the plan. The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calendar year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's Common Stock on the Exercise Date of such Offering Period, whichever is lower. During the year ended December 31, 2014, 65,441 shares were issued under the employee stock purchase plan. At December 31, 2014, the Company had 434,559 shares of the Company's common stock available for future grant in connection with this plan. | ||||||||||||||||||||||||||
Equity Issuances | ||||||||||||||||||||||||||
In September 2011, the Company entered into a common stock Purchase Agreement (the “Initial Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that Aspire Capital was committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term. In August, 2012, the Initial Purchase Agreement was extended for an additional 24-month term through September 2015. During the three months ended March 31, 2014, the Company issued 0.8 million shares of Common Stock under the provisions the Initial Purchase Agreement for gross proceeds of approximately $5.6 million. As a result, the full $20.0 million worth of shares of the Company's stock have been issued under the Initial Purchase Agreement. | ||||||||||||||||||||||||||
In March 2014, the Company entered into a new common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of Volume Weighted Average Price purchases), in each case as determined by parameters defined in the Purchase Agreement. As consideration for entering into the Purchase Agreement, we issued 150,000 shares of our common stock to Aspire Capital. During the year ended December 31, 2014, the Company issued 1.6 million shares of Common Stock under the provisions of the Purchase Agreement with Aspire for gross proceeds of approximately $10.9 million. As of December 31, 2014, the remaining amount available to the Company under the Purchase Agreement was $19.1 million. | ||||||||||||||||||||||||||
Option Exercises | ||||||||||||||||||||||||||
During the year ended December 31, 2014, option holders exercised an aggregate of 48,987 options at exercise prices between $5.20 and $6.20 per share for gross proceeds of approximately $0.3 million. | ||||||||||||||||||||||||||
Warrant Exercises | ||||||||||||||||||||||||||
During the year ended December 31, 2014, warrant holders exercised an aggregate of 333,250 warrants at an exercise price of $5.16 per share for gross proceeds of approximately $1.7 million. | ||||||||||||||||||||||||||
Stock Options and Warrants | ||||||||||||||||||||||||||
The following table summarizes the activity for stock options and warrants for the years ended December 31, 2014 and December 31, 2013: | ||||||||||||||||||||||||||
Stock Options | Warrants | |||||||||||||||||||||||||
Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value (In Thousands) | Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value (In Thousands) | |||||||||||||||||||
Outstanding at December 31, 2013 | 2,932,191 | $ | 11.19 | 6.81 years | $ | 1,658.10 | 4,898,266 | $ | 16.5 | 2.63 | $ | 1,811.00 | ||||||||||||||
Changes during the Year: | ||||||||||||||||||||||||||
Granted | 2,265,850 | $ | 6.72 | 2,722 | $ | 12.26 | ||||||||||||||||||||
Exercised | (48,987 | ) | $ | 5.53 | (333,250 | ) | $ | 5.16 | ||||||||||||||||||
Forfeited | (368,704 | ) | $ | 6.78 | (100,108 | ) | $ | 70 | ||||||||||||||||||
Expired | (353,116 | ) | $ | 12.94 | (916,674 | ) | $ | 23.95 | ||||||||||||||||||
Outstanding at December 31, 2014 | 4,427,234 | $ | 9.19 | 6.93 | $ | 28.6 | 3,550,956 | $ | 14.12 | 2.12 | $ | 1 | ||||||||||||||
Vested at December 31, 2014 or expected to vest in the future | 4,253,465 | $ | 9.28 | 6.84 | $ | 27 | 3,550,956 | $ | 14.12 | 2.12 | $ | 1 | ||||||||||||||
Exercisable at December 31, 2014 | 2,968,379 | $ | 10.22 | 6.11 | $ | 16.6 | 3,543,456 | $ | 14.13 | 2.12 | $ | 1 | ||||||||||||||
The total intrinsic value of stock options exercised during the years ended December 31, 2014 and December 31, 2013 was $61,641 and $104,360, respectively. | ||||||||||||||||||||||||||
During the years ended December 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data): | ||||||||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||||||||
2014 | 2013 | |||||||||||||||||||||||||
Number of Common Stock Purchase Warrants Issued | — | 40,407 | ||||||||||||||||||||||||
Value of Common Stock Purchase Warrants Issued | $ | — | $ | 149.9 | ||||||||||||||||||||||
Restricted Stock | ||||||||||||||||||||||||||
During the years ended December 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data): | ||||||||||||||||||||||||||
2014 | 2013 | |||||||||||||||||||||||||
Number of Restricted Stock Issued | 917,907 | 514,700 | ||||||||||||||||||||||||
Value of Restricted Stock Issued | $ | 4,996.30 | $ | 3,360.00 | ||||||||||||||||||||||
The weighted average estimated fair value of restricted stock issued for services in the years ended December 31, 2014 and 2013 was $5.44 and $6.53 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year. |
ShareBased_Compensation_Notes
Share-Based Compensation (Notes) | 12 Months Ended | ||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||
Share-based Compensation [Abstract] | |||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | Share-Based Compensation | ||||||||||||||||||||||||
Share-based Compensation | |||||||||||||||||||||||||
We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the years ended December 31, 2014 and 2013 ($ in thousands): | |||||||||||||||||||||||||
Year Ended December 31, | |||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||
Cost of revenues | $ | 494.2 | $ | 314 | $ | 195 | |||||||||||||||||||
Research and development | 2,058.20 | 822.2 | 432.9 | ||||||||||||||||||||||
Selling, general and administrative | 8,657.10 | 5,702.50 | 6,084.60 | ||||||||||||||||||||||
Total share-based compensation expense | $ | 11,209.50 | $ | 6,838.70 | $ | 6,712.50 | |||||||||||||||||||
Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2014 were as follows ($ in thousands): | |||||||||||||||||||||||||
Stock Options | Warrants | Restricted Stock | |||||||||||||||||||||||
Unrecognized compensation cost | $ | 4,598.40 | $ | 7.2 | $ | 528.6 | |||||||||||||||||||
Expected weighted-average period in years of compensation cost to be recognized | 3.79 | 0.54 | 0.31 | ||||||||||||||||||||||
Total fair value of shares vested and the weighted average estimated fair values of shares grant for the year ended December 31, 2014, 2013, and 2012 were as follows ($ in thousands): | |||||||||||||||||||||||||
Stock Options | Warrants | ||||||||||||||||||||||||
Year Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||
2014 | 2013 | 2012 | 2014 | 2013 | 2012 | ||||||||||||||||||||
Total fair value of shares vested | $ | 5,387.10 | $ | 3,375.70 | $ | 5,408.00 | $ | 9.6 | $ | 129 | $ | 171.6 | |||||||||||||
Weighted average estimated fair value of shares granted | 4.56 | 4.29 | 3.63 | — | 3.71 | 4.1 | |||||||||||||||||||
Valuation Assumptions | |||||||||||||||||||||||||
The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants. | |||||||||||||||||||||||||
The range of assumptions made in calculating the fair values of stock options and warrants was as follow: | |||||||||||||||||||||||||
Stock Options | Warrants | ||||||||||||||||||||||||
Year Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||
2014 | 2013 | 2012 | 2014 | 2013 | 2012 | ||||||||||||||||||||
Expected term - minimum (in years) | 0 | 1 | 2 | 3 | 2 | 2 | |||||||||||||||||||
Expected term - maximum (in years) | 10 | 10 | 10 | 3 | 5 | 5 | |||||||||||||||||||
Expected volatility - minimum | 62% | 61% | 73% | 66% | 73% | 76% | |||||||||||||||||||
Expected volatility - maximum | 77% | 79% | 84% | 66% | 79% | 83% | |||||||||||||||||||
Weighted Average volatility | 74 | % | 72 | % | 83 | % | 66 | % | 74 | % | 82 | % | |||||||||||||
Expected dividend yield | — | — | — | — | — | — | |||||||||||||||||||
Risk-free interest rate - minimum | 0.12% | 0.13% | 0.28% | 0.79% | 0.32% | 0.27% | |||||||||||||||||||
Risk-free interest rate - maximum | 3.00% | 2.67% | 1.99% | 0.79% | 1.73% | 0.88% |
Income_Taxes
Income Taxes | 12 Months Ended | ||||||||||||
Dec. 31, 2014 | |||||||||||||
Income Taxes [Abstract] | |||||||||||||
Income Tax Disclosure [Text Block] | Income Taxes | ||||||||||||
The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
United States | $ | (55,570.4 | ) | $ | (38,705.2 | ) | $ | (36,276.9 | ) | ||||
$ | (55,570.4 | ) | $ | (38,705.2 | ) | $ | (36,276.9 | ) | |||||
The provision (benefit) for income taxes was as follows ($ in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
Current | |||||||||||||
US Federal | $ | — | $ | — | $ | — | |||||||
State and local | — | — | — | ||||||||||
$ | — | $ | — | $ | — | ||||||||
Deferred | |||||||||||||
US Federal | $ | 159 | $ | 476.9 | $ | — | |||||||
State and local | (263.2 | ) | 303.2 | (175.5 | ) | ||||||||
$ | (104.2 | ) | $ | 780.1 | $ | (175.5 | ) | ||||||
Total | |||||||||||||
US Federal | $ | 159 | $ | 476.9 | $ | — | |||||||
State and local | (263.2 | ) | 303.2 | (175.5 | ) | ||||||||
$ | (104.2 | ) | $ | 780.1 | $ | (175.5 | ) | ||||||
The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 34% to income before income taxes as a result of the following ($ in thousands): | |||||||||||||
Years Ended December 31, | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
U.S. Federal benefit at statutory rate | $ | (18,894.0 | ) | $ | (13,159.8 | ) | $ | (12,334.1 | ) | ||||
State and local benefit net of U.S. federal tax | (3,435.0 | ) | (3,430.9 | ) | (2,154.1 | ) | |||||||
Permanent non deductible expenses for U.S. taxes | 1,094.60 | 1,798.20 | (2,781.4 | ) | |||||||||
True-up of prior year net operating loss | (25.5 | ) | (91.4 | ) | 321.6 | ||||||||
Return to actual | — | (3,822.9 | ) | (384.8 | ) | ||||||||
Foreign earnings not permanently reinvested | — | — | (1,810.3 | ) | |||||||||
Effect of change in deferred tax rate | 1,075.70 | (1,094.8 | ) | 525.7 | |||||||||
Valuation allowance for deferred tax assets | 20,080.00 | 20,581.70 | 18,441.90 | ||||||||||
Tax provision | $ | (104.2 | ) | $ | 780.1 | $ | (175.5 | ) | |||||
Deferred income taxes at December 31, 2014, 2013 and 2012 consist of the following ($ in thousands): | |||||||||||||
December 31, | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
Deferred Tax Assets: | |||||||||||||
Accumulated net operating losses (tax effected) | $ | 69,047.00 | $ | 43,334.80 | $ | 25,727.70 | |||||||
Deferred revenue | — | 10.5 | 23.1 | ||||||||||
Contingent accounts payable | (7.8 | ) | 13.6 | 15.2 | |||||||||
Share-based compensation | 9,577.20 | 7,971.90 | 5,466.70 | ||||||||||
Intangibles | 715.1 | 704.6 | 287.3 | ||||||||||
Accumulated depreciation | — | — | 348.7 | ||||||||||
Charitable contributions | 409.8 | 414.9 | 391.8 | ||||||||||
Bad debt provision | 296.9 | 304.3 | 239.7 | ||||||||||
Capital loss carry-forward | 6,925.10 | 7,036.80 | 6,644.50 | ||||||||||
Other | 609.7 | — | — | ||||||||||
Deferred tax assets prior to tax credit carryovers | 87,573.00 | 59,791.40 | 39,144.70 | ||||||||||
Deferred Tax Liabilities: | |||||||||||||
Accumulated depreciation | $ | (18.8 | ) | $ | (64.8 | ) | $ | — | |||||
Intangible and indefinite lived assets | (18,176.3 | ) | (4,379.2 | ) | (3,599.1 | ) | |||||||
Deferred tax liabilities | (18,195.1 | ) | (4,444.0 | ) | (3,599.1 | ) | |||||||
69,377.90 | 55,347.40 | 35,545.60 | |||||||||||
Valuation reserve | (87,554.1 | ) | (59,726.6 | ) | (39,144.7 | ) | |||||||
Net deferred tax liability | $ | (18,176.2 | ) | $ | (4,379.2 | ) | $ | (3,599.1 | ) | ||||
In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time. | |||||||||||||
As of December 31, 2014 and 2013, the Company had approximately $177.2 million and $110.6 million, respectively of Federal NOLs available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2032. | |||||||||||||
The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense. | |||||||||||||
As of December 31, 2014, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year. | |||||||||||||
The Federal tax returns are currently being audited for the years 2012 and 2013. For years prior to 2011 the federal statute of limitations is closed. Most of the remaining states remain open to examination for a period of 3 to 4 years from date of filing. The Company files tax returns in all of the foreign jurisdictions that it has a permanent establishment and the tax filings remain subject to examination for 4 to 5 years. |
Discontinued_Operations
Discontinued Operations | 12 Months Ended | |||
Dec. 31, 2014 | ||||
Discontinued Operations [Abstract] | ||||
Discontinued Operations [Text Block] | Discontinued Operations | |||
Regenerative Medicine - China segment | ||||
In the first quarter of 2012, the Company exited its regenerative medicine business in the People's Republic of China. As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands): | ||||
Cash | $ | 195.1 | ||
Prepaid expenses and other current assets | 14.9 | |||
Property, plant and equipment, net | 1,023.70 | |||
Other Assets | 330.5 | |||
Accounts payable | (177.1 | ) | ||
Accrued liabilities | (79.2 | ) | ||
Accumulated comprehensive income | (169.9 | ) | ||
Loss on exit of segment | $ | 1,138.00 | ||
The operations and cash flows of the Regenerative Medicine - China business were eliminated from ongoing operations as a result of our exit decision, and the Company will not have continuing involvement in this business going forward. The operating results of the Regenerative Medicine – China business for the year ended December 31, 2012, which are included in discontinued operations, were as follows (in thousands): | ||||
Year Ended December 31, | ||||
2012 | ||||
Revenue | $ | 52.3 | ||
Cost of revenues | (30.6 | ) | ||
Research and development | (103.3 | ) | ||
Selling, general, and administrative | (497.3 | ) | ||
Other income (expense) | (6.8 | ) | ||
Loss on exit of segment | (1,138.0 | ) | ||
Loss from discontinued operations | $ | (1,723.7 | ) | |
Pharmaceutical Manufacturing - China segment | ||||
On November 13, 2012, the Company completed the divestiture of its 51% interest (the “Erye Interest”) in Suzhou Erye Pharmaceuticals Company Ltd., a Sino-foreign equity joint venture with limited liability organized under the laws of the People's Republic of China. Pursuant to the Equity Purchase Agreement, the aggregate purchase price paid to the Company for the Erye Interest consisted of (i) approximately $12.3 million in cash, (ii) the return to the Company of 104,000 shares of NeoStem common stock and (iii) the cancellation of 117,000 options and 64,000 warrants to purchase our common stock. The fair value of the shares was based on the Company's closing price on the date of sale, and was recorded as Treasury Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet. The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands): | ||||
Fair value of consideration received | $ | 13,397.90 | ||
Carrying value of segment non-controlling interest | 6,015.00 | |||
Carrying value of segment accumulated comprehensive income | 4,387.40 | |||
$ | 23,800.30 | |||
Less carrying amount of assets and liabilities sold: | ||||
Cash | $ | 8,457.50 | ||
Restricted Cash | 2,918.10 | |||
Accounts Receivable | 6,130.20 | |||
Inventories | 15,077.70 | |||
Prepaid expenses and other current assets | 957.8 | |||
Property, plant and equipment, net | 38,102.00 | |||
Other assets | 5,946.30 | |||
Accounts payable | (9,604.8 | ) | ||
Accrued liabilities | (2,008.8 | ) | ||
Bank loans | (15,133.5 | ) | ||
Notes payable | (6,599.3 | ) | ||
Other liabilities | (9,166.8 | ) | ||
Amount due related party | (7,859.7 | ) | ||
$ | 27,216.70 | |||
Loss on exit of segment | $ | (3,416.4 | ) | |
The operations and cash flows of the Pharmaceutical Manufacturing - China business were eliminated from ongoing operations with the sale of the Company's Erye Interest. The operating results of the Pharmaceutical Manufacturing - China business for the year ended December 31, 2012, which are included in discontinued operations, were as follows (in thousands): | ||||
Year Ended December 31, | ||||
2012 | ||||
Revenue | $ | 61,703.10 | ||
Cost of revenues | (40,245.2 | ) | ||
Research and development | (1,836.4 | ) | ||
Selling, general, and administrative | (10,740.0 | ) | ||
Other expense | (1,045.2 | ) | ||
Provision for income taxes | (1,794.1 | ) | ||
Asset impairments | (31,170.1 | ) | ||
Loss on sale of segment | (3,416.4 | ) | ||
Loss from discontinued operations | $ | (28,544.3 | ) | |
Related_Party_Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2014 | |
Related Party Transactions [Abstract] | |
Related Party Transactions [Text Block] | On November 13, 2012, we and our subsidiary, CBH, sold our 51% ownership interest in Erye to Fullbright and EET (see Note 15). EET was prior to the sale the holder of the minority 49% ownership interest in Erye, and was a party along with our subsidiary CBH to the Joint Venture Agreement which had governed the ownership of the respective interests in Erye. Fullbright is an affiliate of EET. Mr. Shi Mingsheng (a former member of our Board of Directors, and Chairman of the Board of Erye) and Madam Zhang Jian (the General Manager of Erye, and formerly our Vice President of Pharmaceutical Operations) are the principal equity holders of each of EET and Fullbright. Fullbright assigned all its rights and obligations under the Equity Purchase Agreement (except for its obligations in respect of the return of certain NeoStem securities held by it as part of the purchase price, and its obligations in respect of closing deliverables) to Highacheive Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands and an affiliate of Fullbright (“Highacheive”). As a result of the assignment, the Purchasers of our Erye Interest were EET and Highacheive. |
In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. (see Note 11). Pursuant to the Loan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, including Dr. Pecora, have been released as guarantors of the Second Mortgage Loan, and NeoStem has become a guarantor of the Loans pursuant to a Guaranty of Payment delivered by NeoStem to the Lender. Dr. Pecora, currently currently serves as a NeoStem director, NeoStem’s Chief Visionary Officer, PCT’s Chief Medical Officer and Amorcyte’s Chief Scientific Officer. |
Commitments_and_Contingencies
Commitments and Contingencies | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
Commitments and Contingencies [Abstract] | |||||
Commitments and Contingencies [Text Block] | Commitments and Contingencies | ||||
Lease Commitments | |||||
The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2018. In January 2014, the Company signed a new lease for a larger space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease shall extend through 2018. This property is used as the Company's corporate headquarters. In connection with the CSC Acquisition on May 8, 2014, the Company assumed a facility lease in Irvine, California, with a termination at the end of 2017. We recently signed an amendment expanding our office space in Irvine by 4,000 square feet, and extending the term through 2021. In accordance with the amendment, we plan to occupy the additional space by the second quarter of 2015. | |||||
A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2014 are as follows (in thousands): | |||||
Years ended | Operating Leases | ||||
2015 | $ | 1,567.90 | |||
2016 | 1,656.90 | ||||
2017 | 1,367.30 | ||||
2018 | 535.2 | ||||
2019 | 492.4 | ||||
2020 and thereafter | 628.1 | ||||
Total minimum lease payments | $ | 6,247.80 | |||
Expense incurred under operating leases were approximately $1.3 million , $1.1 million , and $1.5 million for the years ended December 31, 2014, 2013, and 2012, respectively. | |||||
Contingencies | |||||
Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research. | |||||
From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. |
Subsequent_Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2014 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | Subsequent Events |
New Facility Lease | |
We recently entered into an assignment agreement, effective February 19, 2015, for general office space located in Basking Ridge, New Jersey. The space is approximately 18,467 rentable square feet. Pursuant to the agreement, we are not obligated to make any payments for the space until January 2016.The base monthly rent during the period ending January 31, 2016 is currently $25,000 and the lease term ends July 31, 2020. In addition, there are two (2) five (5) year renewal options. In connection with the assumption of the lease, the third party (a) conveyed its rights in various scheduled furniture and equipment and (b) paid the Company approximately $580,000 which amount will offset the rental payments to be paid by NeoStem. A security deposit of approximately $115,000 payable by NeoStem will offset the amount payable by the third party. | |
Common Stock Issuances | |
Pursuant to the Purchase Agreement with Aspire (see Note 12), from January 1, 2015 through March 1, 2015, Aspire has purchased 1.2 million shares of the Company's common stock for an aggregate consideration of approximately $4.4 million. |
AvailableforSaleSecurities_Not
Available-for-Sale-Securities (Notes) | 12 Months Ended | |||||||||||||||
Dec. 31, 2014 | ||||||||||||||||
Available-for-sale Securities [Abstract] | ||||||||||||||||
Cash, Cash Equivalents, and Marketable Securities [Text Block] | Available-for-Sale-Securities | |||||||||||||||
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands): | ||||||||||||||||
December 31, 2014 | ||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | |||||||||||||
Certificate of deposits | $ | 249 | $ | — | $ | — | $ | 249 | ||||||||
Money market funds | 12,791.90 | — | — | 12,791.90 | ||||||||||||
Municipal debt securities | 9,317.30 | 1.3 | — | 9,318.60 | ||||||||||||
Total | $ | 22,358.20 | $ | 1.3 | $ | — | $ | 22,359.50 | ||||||||
Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands): | ||||||||||||||||
December 31, 2014 | ||||||||||||||||
Cash and cash equivalents | $ | 15,279.40 | ||||||||||||||
Marketable securities | 7,080.10 | |||||||||||||||
Total | $ | 22,359.50 | ||||||||||||||
The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands): | ||||||||||||||||
December 31, 2014 | ||||||||||||||||
Amortized Cost | Estimated Fair Value | |||||||||||||||
Less than one year | $ | 22,358.20 | $ | 22,359.50 | ||||||||||||
Greater than one year | — | — | ||||||||||||||
Total | $ | 22,358.20 | $ | 22,359.50 | ||||||||||||
Quarterly_Financial_Data_Notes
Quarterly Financial Data (Notes) | 12 Months Ended | |||||||||||||||
Dec. 31, 2014 | ||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ||||||||||||||||
Quarterly Financial Information [Text Block] | Quarterly Financial Data (unaudited) | |||||||||||||||
The tables below summarize the Company's unaudited quarterly operating results for the years ended December 31, 2014 and 2013, respectively. | ||||||||||||||||
Three Months Ended | ||||||||||||||||
(in thousands, except per share data) | March 31, 2014 | June 30, 2014 | September 30, 2014 | December 31, 2014 | ||||||||||||
Revenues | $ | 4,056 | $ | 4,489 | $ | 4,118 | $ | 5,276 | ||||||||
Total operating costs and expenses | $ | 17,555 | $ | 16,919 | $ | 20,376 | $ | 20,830 | ||||||||
Net loss from continuing operations | $ | (13,830 | ) | $ | (12,769 | ) | $ | (17,177 | ) | $ | (11,691 | ) | ||||
Net loss attributable to NeoStem, Inc. common stockholders | $ | (13,682 | ) | $ | (12,605 | ) | $ | (16,974 | ) | $ | (11,612 | ) | ||||
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders | $ | (0.49 | ) | $ | (0.40 | ) | $ | (0.48 | ) | $ | (0.32 | ) | ||||
Three Months Ended | ||||||||||||||||
(in thousands, except per share data) | March 31, 2013 | June 30, 2013 | September 30, 2013 | December 31, 2013 | ||||||||||||
Revenues | $ | 2,524 | $ | 4,359 | $ | 3,707 | $ | 4,078 | ||||||||
Total operating costs and expenses | $ | 11,355 | $ | 12,530 | $ | 13,020 | $ | 14,573 | ||||||||
Net loss from continuing operations | $ | (8,864 | ) | $ | (8,626 | ) | $ | (9,277 | ) | $ | (12,719 | ) | ||||
Net loss attributable to NeoStem, Inc. common stockholders | $ | (8,801 | ) | $ | (8,575 | ) | $ | (9,071 | ) | $ | (12,535 | ) | ||||
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders | $ | (0.53 | ) | $ | (0.46 | ) | $ | (0.45 | ) | $ | (0.47 | ) |
The_Business_Tables
The Business (Tables) | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
The Business [Abstract] | |||||
Subsidiary [Table Text Block] | These former segments are reported in discontinued operations. | ||||
Entity | Percentage of Ownership | Location | |||
NeoStem, Inc. | 100% | United States of America | |||
NeoStem Therapies, Inc. | 100% | United States of America | |||
Stem Cell Technologies, Inc. | 100% | United States of America | |||
Amorcyte, LLC | 100% | United States of America | |||
Progenitor Cell Therapy, LLC (PCT) | 100% | United States of America | |||
NeoStem Family Storage, LLC | 100% | United States of America | |||
Athelos Corporation (1) | 96.20% | United States of America | |||
PCT Allendale, LLC | 100% | United States of America | |||
NeoStem Oncology, LLC (2) | 100% | United States of America |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Accounting Policies [Abstract] | |||||||||
Property, Plant and Equipment [Table Text Block] | |||||||||
Building and improvements | 25-30 years | ||||||||
Machinery and equipment | 8-12 years | ||||||||
Lab equipment | 5-7 years | ||||||||
Furniture and fixtures | 5-12 years | ||||||||
Software | 3-5 years | ||||||||
Leasehold improvements | Life of lease | ||||||||
Property, plant, and equipment consisted of the following (in thousands): | |||||||||
December 31, | |||||||||
2014 | 2013 | ||||||||
Building and improvements | $ | 11,298.70 | $ | 11,229.90 | |||||
Machinery and equipment | 68.3 | 58.2 | |||||||
Lab equipment | 6,324.70 | 2,743.70 | |||||||
Furniture and fixtures | 1,166.30 | 958 | |||||||
Software | 312.4 | 203.1 | |||||||
Leasehold improvements | 2,219.60 | 674.1 | |||||||
Property, plant and equipment, gross | 21,390.00 | 15,867.00 | |||||||
Accumulated depreciation | (5,429.3 | ) | (3,022.8 | ) | |||||
Property, plant and equipment, net | $ | 15,960.70 | $ | 12,844.20 | |||||
Revenue Recognition, Policy [Policy Text Block] | Treasury Stock | ||||||||
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital. | |||||||||
Revenue Recognition | |||||||||
Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts. | |||||||||
We recognize revenues when all of the following conditions are met: | |||||||||
• | persuasive evidence of an arrangement exists; | ||||||||
• | delivery has occurred or the services have been rendered; | ||||||||
• | the fee is fixed or determinable; and | ||||||||
• | collectability is probable. | ||||||||
The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform. | |||||||||
Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. Progress billings collected prior to contract completion are recorded as unearned revenue until such time the contract is completed, which usually requires formal client acceptance. | |||||||||
Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met. | |||||||||
Some client agreements include multiple elements, comprised of cell process development and cell manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price. | |||||||||
Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the years ended December 31, 2014, 2013, and 2012, clinical services reimbursements were $3.7 million, $2.1 million, and $3.5 million, respectively. | |||||||||
Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments. | |||||||||
Property, Plant and Equipment, Policy [Policy Text Block] | The cost of property, plant and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property, plant and equipment are as follows: | ||||||||
Building and improvements | 25-30 years | ||||||||
Machinery and equipment | 8-12 years | ||||||||
Lab equipment | 5-7 years | ||||||||
Furniture and fixtures | 5-12 years | ||||||||
Software | 3-5 years | ||||||||
Leasehold improvements | Life of lease |
Acquisitions_Tables
Acquisitions (Tables) | 12 Months Ended | |||||||||||||||
Dec. 31, 2014 | ||||||||||||||||
Identified Assets Acquired [Abstract] | ||||||||||||||||
Business Acquisition, Pro Forma Information [Table Text Block] | The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the acquisition of CSC had occurred on January 1, 2013 (in thousands, except per share amounts): | |||||||||||||||
Twelve Months Ended December 31, 2014 | Twelve Months Ended December 31, 2013 | |||||||||||||||
(As Reported) | (Proforma -Unaudited) | (As Reported) | (Proforma -Unaudited) | |||||||||||||
Revenues | $ | 17,939 | $ | 18,649 | $ | 14,668 | $ | 15,471 | ||||||||
Net loss | $ | (55,467 | ) | $ | (57,964 | ) | $ | (39,485 | ) | $ | (44,790 | ) | ||||
Net loss attributable to NeoStem | $ | (54,873 | ) | $ | (57,371 | ) | $ | (38,981 | ) | $ | (44,286 | ) | ||||
Net loss per share attributable to NeoStem | $ | (1.68 | ) | $ | (1.51 | ) | $ | (1.90 | ) | $ | (1.71 | ) | ||||
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands): | |||||||||||||||
Cash and cash equivalents | $ | 51 | ||||||||||||||
Accounts receivable trade, net | 45 | |||||||||||||||
Prepaids and other current assets | 19 | |||||||||||||||
Property, plant and equipment, net | 1,041 | |||||||||||||||
Other assets | 201 | |||||||||||||||
Goodwill | 14,092 | |||||||||||||||
In-Process R&D | 34,290 | |||||||||||||||
Accounts payable | (333 | ) | ||||||||||||||
Accrued liabilities | (2,014 | ) | ||||||||||||||
Deferred tax liability | (13,901 | ) | ||||||||||||||
$ | 33,491 | |||||||||||||||
AvailabeforSaleSecurities_sche
Availabe-for-Sale-Securities schedule of available-for-Sales (Tables) | 12 Months Ended | |||||||||||||||
Dec. 31, 2014 | ||||||||||||||||
Available-for-sale Securities [Abstract] | ||||||||||||||||
Schedule of Available-for-sale Securities Reconciliation [Table Text Block] | The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands): | |||||||||||||||
December 31, 2014 | ||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | |||||||||||||
Certificate of deposits | $ | 249 | $ | — | $ | — | $ | 249 | ||||||||
Money market funds | 12,791.90 | — | — | 12,791.90 | ||||||||||||
Municipal debt securities | 9,317.30 | 1.3 | — | 9,318.60 | ||||||||||||
Total | $ | 22,358.20 | $ | 1.3 | $ | — | $ | 22,359.50 | ||||||||
Marketable Securities [Table Text Block] | Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands): | |||||||||||||||
December 31, 2014 | ||||||||||||||||
Cash and cash equivalents | $ | 15,279.40 | ||||||||||||||
Marketable securities | 7,080.10 | |||||||||||||||
Total | $ | 22,359.50 | ||||||||||||||
Investments Classified by Contractual Maturity Date [Table Text Block] | The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands): | |||||||||||||||
December 31, 2014 | ||||||||||||||||
Amortized Cost | Estimated Fair Value | |||||||||||||||
Less than one year | $ | 22,358.20 | $ | 22,359.50 | ||||||||||||
Greater than one year | — | — | ||||||||||||||
Total | $ | 22,358.20 | $ | 22,359.50 | ||||||||||||
Property_Plant_Equipment_Table
Property, Plant & Equipment (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Property, Plant and Equipment [Abstract] | |||||||||
Property, Plant and Equipment [Table Text Block] | |||||||||
Building and improvements | 25-30 years | ||||||||
Machinery and equipment | 8-12 years | ||||||||
Lab equipment | 5-7 years | ||||||||
Furniture and fixtures | 5-12 years | ||||||||
Software | 3-5 years | ||||||||
Leasehold improvements | Life of lease | ||||||||
Property, plant, and equipment consisted of the following (in thousands): | |||||||||
December 31, | |||||||||
2014 | 2013 | ||||||||
Building and improvements | $ | 11,298.70 | $ | 11,229.90 | |||||
Machinery and equipment | 68.3 | 58.2 | |||||||
Lab equipment | 6,324.70 | 2,743.70 | |||||||
Furniture and fixtures | 1,166.30 | 958 | |||||||
Software | 312.4 | 203.1 | |||||||
Leasehold improvements | 2,219.60 | 674.1 | |||||||
Property, plant and equipment, gross | 21,390.00 | 15,867.00 | |||||||
Accumulated depreciation | (5,429.3 | ) | (3,022.8 | ) | |||||
Property, plant and equipment, net | $ | 15,960.70 | $ | 12,844.20 | |||||
Loss_Per_Share_Tables
Loss Per Share (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Loss Per Share [Abstract] | |||||||||
Loss Per Share [Text Block] | Loss Per Share | ||||||||
For the years ended December 31, 2014, 2013, and 2012 the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive in the periods presented. At December 31, 2014, 2013, and 2012 the Company excluded the following potentially dilutive securities: | |||||||||
December 31, | |||||||||
2014 | 2013 | 2012 | |||||||
Stock Options | 4,427,276 | 2,932,191 | 2,168,668 | ||||||
Warrants | 3,550,956 | 4,898,266 | 5,528,761 | ||||||
Restricted Shares | 280,481 | 78,500 | 34,250 | ||||||
ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block] | At December 31, 2014, 2013, and 2012 the Company excluded the following potentially dilutive securities: | ||||||||
December 31, | |||||||||
2014 | 2013 | 2012 | |||||||
Stock Options | 4,427,276 | 2,932,191 | 2,168,668 | ||||||
Warrants | 3,550,956 | 4,898,266 | 5,528,761 | ||||||
Restricted Shares | 280,481 | 78,500 | 34,250 | ||||||
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||||||||
Fair Value Measurements [Abstract] | |||||||||||||||||||||||||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block] | The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2014, and December 31, 2013 (in thousands): | ||||||||||||||||||||||||||||||||
December 31, 2014 | December 31, 2013 | ||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||
Assets: | |||||||||||||||||||||||||||||||||
Marketable securities - available for sale | $ | — | $ | 7,080.00 | $ | — | $ | 7,080.00 | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||
$ | — | $ | 7,080.00 | $ | — | $ | 7,080.00 | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||
Liabilities: | |||||||||||||||||||||||||||||||||
Warrant derivative liabilities | — | — | — | — | — | — | 23.2 | 23.2 | |||||||||||||||||||||||||
Contingent consideration | — | — | 18,260.00 | 18,260.00 | — | — | 9,450.00 | 9,450.00 | |||||||||||||||||||||||||
$ | — | $ | — | $ | 18,260.00 | $ | 18,260.00 | $ | — | $ | — | $ | 9,473.20 | $ | 9,473.20 | ||||||||||||||||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2014 by type of instrument (in thousands): | ||||||||||||||||||||||||||||||||
Year Ended | |||||||||||||||||||||||||||||||||
December 31, 2014 | |||||||||||||||||||||||||||||||||
Warrants | Contingent Consideration | Total | |||||||||||||||||||||||||||||||
Beginning liability balance | $ | 23.2 | $ | 9,450.00 | $ | 9,473.20 | |||||||||||||||||||||||||||
Amount issued in acquisition | — | 11,890.00 | 11,890.00 | ||||||||||||||||||||||||||||||
Change in fair value recorded in operations | — | (3,080.0 | ) | (3,080.0 | ) | ||||||||||||||||||||||||||||
Expiration | (23.2 | ) | — | (23.2 | ) | ||||||||||||||||||||||||||||
Ending liability balance | $ | — | $ | 18,260.00 | $ | 18,260.00 | |||||||||||||||||||||||||||
Goodwill_and_Other_Intangible_1
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended | |||||||||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||||||||
Goodwill and Other Intangible Assets [Abstract] | ||||||||||||||||||||||||||
Schedule of Goodwill [Table Text Block] | thousands): | |||||||||||||||||||||||||
Total | ||||||||||||||||||||||||||
Balance as of December 31, 2013 | $ | 11,117.80 | ||||||||||||||||||||||||
Goodwill resulting from the acquisition of CSC | 14,091.50 | |||||||||||||||||||||||||
Balance as of December 31, 2014 | $ | 25,209.30 | ||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block] | s of December 31, 2014 and December 31, 2013 consisted of the following (in thousands): | |||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | |||||||||||||||||||||||||
Useful Life | Gross | Accumulated Amortization | Net | Gross | Accumulated Amortization | Net | ||||||||||||||||||||
Customer list | 10 years | $ | 1,000.00 | $ | (395.1 | ) | $ | 604.9 | $ | 1,000.00 | $ | (295.1 | ) | $ | 704.9 | |||||||||||
Manufacturing technology | 10 years | 3,900.00 | (1,540.9 | ) | 2,359.10 | 3,900.00 | (1,150.9 | ) | 2,749.10 | |||||||||||||||||
Tradename | 10 years | 800 | (316.1 | ) | 483.9 | 800 | (236.1 | ) | 563.9 | |||||||||||||||||
In process R&D | Indefinite | 43,690.00 | — | 43,690.00 | 9,400.00 | — | 9,400.00 | |||||||||||||||||||
Patent rights | 19 years | 669 | (246.5 | ) | 422.5 | 669 | (211.3 | ) | 457.7 | |||||||||||||||||
Total Intangible Assets | $ | 50,059.00 | $ | (2,498.6 | ) | $ | 47,560.40 | $ | 15,769.00 | $ | (1,893.4 | ) | $ | 13,875.60 | ||||||||||||
Schedule of Amortization Expense [Table Text Block] | Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands): | |||||||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||||||||
Cost of revenue | $ | 316.8 | $ | 390 | $ | 390 | ||||||||||||||||||||
Research and development | 108.4 | 35.2 | 35.2 | |||||||||||||||||||||||
Selling, general and administrative | 180 | 180 | 180 | |||||||||||||||||||||||
Total | $ | 605.2 | $ | 605.2 | $ | 605.2 | ||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands): | |||||||||||||||||||||||||
2015 | $ | 605.2 | ||||||||||||||||||||||||
2016 | 605.2 | |||||||||||||||||||||||||
2017 | 605.2 | |||||||||||||||||||||||||
2018 | 605.2 | |||||||||||||||||||||||||
2019 | 605.2 | |||||||||||||||||||||||||
Thereafter | 44,534.40 | |||||||||||||||||||||||||
$ | 47,560.40 | |||||||||||||||||||||||||
Accrued_Liabilities_Accrued_Li
Accrued Liabilities Accrued Liabilities (Tables) | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Accrued Liabilities [Abstract] | ||||||||
Schedule of Accrued Liabilities [Table Text Block] | Accrued liabilities were as follow (in thousands): | |||||||
December 31, | ||||||||
2014 | 2013 | |||||||
Salaries, employee benefits and related taxes | $ | 2,807.20 | $ | 2,325.80 | ||||
Professional fees | 495.4 | 544.8 | ||||||
License fees | — | 500 | ||||||
Other | 1,020.30 | 647.4 | ||||||
$ | 4,322.90 | $ | 4,018.00 | |||||
Debt_Long_term_debt_maturities
Debt Long term debt, maturities (Tables) | 12 Months Ended | |||
Dec. 31, 2014 | ||||
Long-term Debt Disclosure [Abstract] | ||||
Schedule of Maturities of Long-term Debt [Table Text Block] | ||||
Years Ending December 31, | (in millions) | |||
2015 | $ | 2.4 | ||
2016 | 5.7 | |||
2017 | 5.7 | |||
2018 | 5.4 | |||
Total | $ | 19.2 | ||
Shareholders_Equity_Tables
Shareholders' Equity (Tables) | 12 Months Ended | |||||||||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||||||||
Shareholdersb Equity [Abstract] | ||||||||||||||||||||||||||
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] | The number of remaining shares authorized to be issued under the various equity plans are as follows: | |||||||||||||||||||||||||
2003 Equity Plan | 2009 Equity Plan | |||||||||||||||||||||||||
Shares Authorized for Issuance | 250,000 | 8,995,000 | ||||||||||||||||||||||||
Outstanding Stock Options | (122,395 | ) | (4,304,881 | ) | ||||||||||||||||||||||
Exercised Stock Options | (9,250 | ) | (80,856 | ) | ||||||||||||||||||||||
Restricted stock or equity grants issued under Equity Plans | (88,993 | ) | (946,711 | ) | ||||||||||||||||||||||
Shares Expired | (29,362 | ) | — | |||||||||||||||||||||||
Total common shares remaining to be issued under the Equity Plans | — | 3,662,552 | ||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | The following table summarizes the activity for stock options and warrants for the years ended December 31, 2014 and December 31, 2013: | |||||||||||||||||||||||||
Stock Options | Warrants | |||||||||||||||||||||||||
Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value (In Thousands) | Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value (In Thousands) | |||||||||||||||||||
Outstanding at December 31, 2013 | 2,932,191 | $ | 11.19 | 6.81 years | $ | 1,658.10 | 4,898,266 | $ | 16.5 | 2.63 | $ | 1,811.00 | ||||||||||||||
Changes during the Year: | ||||||||||||||||||||||||||
Granted | 2,265,850 | $ | 6.72 | 2,722 | $ | 12.26 | ||||||||||||||||||||
Exercised | (48,987 | ) | $ | 5.53 | (333,250 | ) | $ | 5.16 | ||||||||||||||||||
Forfeited | (368,704 | ) | $ | 6.78 | (100,108 | ) | $ | 70 | ||||||||||||||||||
Expired | (353,116 | ) | $ | 12.94 | (916,674 | ) | $ | 23.95 | ||||||||||||||||||
Outstanding at December 31, 2014 | 4,427,234 | $ | 9.19 | 6.93 | $ | 28.6 | 3,550,956 | $ | 14.12 | 2.12 | $ | 1 | ||||||||||||||
Vested at December 31, 2014 or expected to vest in the future | 4,253,465 | $ | 9.28 | 6.84 | $ | 27 | 3,550,956 | $ | 14.12 | 2.12 | $ | 1 | ||||||||||||||
Exercisable at December 31, 2014 | 2,968,379 | $ | 10.22 | 6.11 | $ | 16.6 | 3,543,456 | $ | 14.13 | 2.12 | $ | 1 | ||||||||||||||
The following table summarizes the components of share-based compensation expense for the years ended December 31, 2014 and 2013 ($ in thousands): | ||||||||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||||||||
Cost of revenues | $ | 494.2 | $ | 314 | $ | 195 | ||||||||||||||||||||
Research and development | 2,058.20 | 822.2 | 432.9 | |||||||||||||||||||||||
Selling, general and administrative | 8,657.10 | 5,702.50 | 6,084.60 | |||||||||||||||||||||||
Total share-based compensation expense | $ | 11,209.50 | $ | 6,838.70 | $ | 6,712.50 | ||||||||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | During the years ended December 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data): | |||||||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||||||||
2014 | 2013 | |||||||||||||||||||||||||
Number of Common Stock Purchase Warrants Issued | — | 40,407 | ||||||||||||||||||||||||
Value of Common Stock Purchase Warrants Issued | $ | — | $ | 149.9 | ||||||||||||||||||||||
Restricted Stock [Table Text Block] | During the years ended December 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data): | |||||||||||||||||||||||||
2014 | 2013 | |||||||||||||||||||||||||
Number of Restricted Stock Issued | 917,907 | 514,700 | ||||||||||||||||||||||||
Value of Restricted Stock Issued | $ | 4,996.30 | $ | 3,360.00 | ||||||||||||||||||||||
ShareBased_Compensation_Tables
Share-Based Compensation (Tables) | 12 Months Ended | |||||||||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||||||||
Share-based Compensation [Abstract] | ||||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | The following table summarizes the activity for stock options and warrants for the years ended December 31, 2014 and December 31, 2013: | |||||||||||||||||||||||||
Stock Options | Warrants | |||||||||||||||||||||||||
Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value (In Thousands) | Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value (In Thousands) | |||||||||||||||||||
Outstanding at December 31, 2013 | 2,932,191 | $ | 11.19 | 6.81 years | $ | 1,658.10 | 4,898,266 | $ | 16.5 | 2.63 | $ | 1,811.00 | ||||||||||||||
Changes during the Year: | ||||||||||||||||||||||||||
Granted | 2,265,850 | $ | 6.72 | 2,722 | $ | 12.26 | ||||||||||||||||||||
Exercised | (48,987 | ) | $ | 5.53 | (333,250 | ) | $ | 5.16 | ||||||||||||||||||
Forfeited | (368,704 | ) | $ | 6.78 | (100,108 | ) | $ | 70 | ||||||||||||||||||
Expired | (353,116 | ) | $ | 12.94 | (916,674 | ) | $ | 23.95 | ||||||||||||||||||
Outstanding at December 31, 2014 | 4,427,234 | $ | 9.19 | 6.93 | $ | 28.6 | 3,550,956 | $ | 14.12 | 2.12 | $ | 1 | ||||||||||||||
Vested at December 31, 2014 or expected to vest in the future | 4,253,465 | $ | 9.28 | 6.84 | $ | 27 | 3,550,956 | $ | 14.12 | 2.12 | $ | 1 | ||||||||||||||
Exercisable at December 31, 2014 | 2,968,379 | $ | 10.22 | 6.11 | $ | 16.6 | 3,543,456 | $ | 14.13 | 2.12 | $ | 1 | ||||||||||||||
The following table summarizes the components of share-based compensation expense for the years ended December 31, 2014 and 2013 ($ in thousands): | ||||||||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||||||||
Cost of revenues | $ | 494.2 | $ | 314 | $ | 195 | ||||||||||||||||||||
Research and development | 2,058.20 | 822.2 | 432.9 | |||||||||||||||||||||||
Selling, general and administrative | 8,657.10 | 5,702.50 | 6,084.60 | |||||||||||||||||||||||
Total share-based compensation expense | $ | 11,209.50 | $ | 6,838.70 | $ | 6,712.50 | ||||||||||||||||||||
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2014 were as follows ($ in thousands): | |||||||||||||||||||||||||
Stock Options | Warrants | Restricted Stock | ||||||||||||||||||||||||
Unrecognized compensation cost | $ | 4,598.40 | $ | 7.2 | $ | 528.6 | ||||||||||||||||||||
Expected weighted-average period in years of compensation cost to be recognized | 3.79 | 0.54 | 0.31 | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] | Total fair value of shares vested and the weighted average estimated fair values of shares grant for the year ended December 31, 2014, 2013, and 2012 were as follows ($ in thousands): | |||||||||||||||||||||||||
Stock Options | Warrants | |||||||||||||||||||||||||
Year Ended December 31, | Year Ended December 31, | |||||||||||||||||||||||||
2014 | 2013 | 2012 | 2014 | 2013 | 2012 | |||||||||||||||||||||
Total fair value of shares vested | $ | 5,387.10 | $ | 3,375.70 | $ | 5,408.00 | $ | 9.6 | $ | 129 | $ | 171.6 | ||||||||||||||
Weighted average estimated fair value of shares granted | 4.56 | 4.29 | 3.63 | — | 3.71 | 4.1 | ||||||||||||||||||||
Schedule of Range of Fair Value of Stock Options and Warrants [Table Text Block] | The range of assumptions made in calculating the fair values of stock options and warrants was as follow: | |||||||||||||||||||||||||
Stock Options | Warrants | |||||||||||||||||||||||||
Year Ended December 31, | Year Ended December 31, | |||||||||||||||||||||||||
2014 | 2013 | 2012 | 2014 | 2013 | 2012 | |||||||||||||||||||||
Expected term - minimum (in years) | 0 | 1 | 2 | 3 | 2 | 2 | ||||||||||||||||||||
Expected term - maximum (in years) | 10 | 10 | 10 | 3 | 5 | 5 | ||||||||||||||||||||
Expected volatility - minimum | 62% | 61% | 73% | 66% | 73% | 76% | ||||||||||||||||||||
Expected volatility - maximum | 77% | 79% | 84% | 66% | 79% | 83% | ||||||||||||||||||||
Weighted Average volatility | 74 | % | 72 | % | 83 | % | 66 | % | 74 | % | 82 | % | ||||||||||||||
Expected dividend yield | — | — | — | — | — | — | ||||||||||||||||||||
Risk-free interest rate - minimum | 0.12% | 0.13% | 0.28% | 0.79% | 0.32% | 0.27% | ||||||||||||||||||||
Risk-free interest rate - maximum | 3.00% | 2.67% | 1.99% | 0.79% | 1.73% | 0.88% |
Income_Taxes_income_taxes_Tabl
Income Taxes income taxes (Tables) | 12 Months Ended | ||||||||||||
Dec. 31, 2014 | |||||||||||||
Income Taxes [Abstract] | |||||||||||||
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | |||||||||||||
Years Ended December 31, | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
U.S. Federal benefit at statutory rate | $ | (18,894.0 | ) | $ | (13,159.8 | ) | $ | (12,334.1 | ) | ||||
State and local benefit net of U.S. federal tax | (3,435.0 | ) | (3,430.9 | ) | (2,154.1 | ) | |||||||
Permanent non deductible expenses for U.S. taxes | 1,094.60 | 1,798.20 | (2,781.4 | ) | |||||||||
True-up of prior year net operating loss | (25.5 | ) | (91.4 | ) | 321.6 | ||||||||
Return to actual | — | (3,822.9 | ) | (384.8 | ) | ||||||||
Foreign earnings not permanently reinvested | — | — | (1,810.3 | ) | |||||||||
Effect of change in deferred tax rate | 1,075.70 | (1,094.8 | ) | 525.7 | |||||||||
Valuation allowance for deferred tax assets | 20,080.00 | 20,581.70 | 18,441.90 | ||||||||||
Tax provision | $ | (104.2 | ) | $ | 780.1 | $ | (175.5 | ) | |||||
Deferred income taxes at December 31, 2014, 2013 and 2012 consist of the following ($ in thousands): | |||||||||||||
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | |||||||||||||
Years Ended December 31, | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
United States | $ | (55,570.4 | ) | $ | (38,705.2 | ) | $ | (36,276.9 | ) | ||||
$ | (55,570.4 | ) | $ | (38,705.2 | ) | $ | (36,276.9 | ) | |||||
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | |||||||||||||
Years Ended December 31, | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
Current | |||||||||||||
US Federal | $ | — | $ | — | $ | — | |||||||
State and local | — | — | — | ||||||||||
$ | — | $ | — | $ | — | ||||||||
Deferred | |||||||||||||
US Federal | $ | 159 | $ | 476.9 | $ | — | |||||||
State and local | (263.2 | ) | 303.2 | (175.5 | ) | ||||||||
$ | (104.2 | ) | $ | 780.1 | $ | (175.5 | ) | ||||||
Total | |||||||||||||
US Federal | $ | 159 | $ | 476.9 | $ | — | |||||||
State and local | (263.2 | ) | 303.2 | (175.5 | ) | ||||||||
$ | (104.2 | ) | $ | 780.1 | $ | (175.5 | ) | ||||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | |||||||||||||
December 31, | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
Deferred Tax Assets: | |||||||||||||
Accumulated net operating losses (tax effected) | $ | 69,047.00 | $ | 43,334.80 | $ | 25,727.70 | |||||||
Deferred revenue | — | 10.5 | 23.1 | ||||||||||
Contingent accounts payable | (7.8 | ) | 13.6 | 15.2 | |||||||||
Share-based compensation | 9,577.20 | 7,971.90 | 5,466.70 | ||||||||||
Intangibles | 715.1 | 704.6 | 287.3 | ||||||||||
Accumulated depreciation | — | — | 348.7 | ||||||||||
Charitable contributions | 409.8 | 414.9 | 391.8 | ||||||||||
Bad debt provision | 296.9 | 304.3 | 239.7 | ||||||||||
Capital loss carry-forward | 6,925.10 | 7,036.80 | 6,644.50 | ||||||||||
Other | 609.7 | — | — | ||||||||||
Deferred tax assets prior to tax credit carryovers | 87,573.00 | 59,791.40 | 39,144.70 | ||||||||||
Deferred Tax Liabilities: | |||||||||||||
Accumulated depreciation | $ | (18.8 | ) | $ | (64.8 | ) | $ | — | |||||
Intangible and indefinite lived assets | (18,176.3 | ) | (4,379.2 | ) | (3,599.1 | ) | |||||||
Deferred tax liabilities | (18,195.1 | ) | (4,444.0 | ) | (3,599.1 | ) | |||||||
69,377.90 | 55,347.40 | 35,545.60 | |||||||||||
Valuation reserve | (87,554.1 | ) | (59,726.6 | ) | (39,144.7 | ) | |||||||
Net deferred tax liability | $ | (18,176.2 | ) | $ | (4,379.2 | ) | $ | (3,599.1 | ) |
Discontinued_Operations_Tables
Discontinued Operations (Tables) | 12 Months Ended | |||
Dec. 31, 2014 | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet. The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands): | |||
Fair value of consideration received | $ | 13,397.90 | ||
Carrying value of segment non-controlling interest | 6,015.00 | |||
Carrying value of segment accumulated comprehensive income | 4,387.40 | |||
$ | 23,800.30 | |||
Less carrying amount of assets and liabilities sold: | ||||
Cash | $ | 8,457.50 | ||
Restricted Cash | 2,918.10 | |||
Accounts Receivable | 6,130.20 | |||
Inventories | 15,077.70 | |||
Prepaid expenses and other current assets | 957.8 | |||
Property, plant and equipment, net | 38,102.00 | |||
Other assets | 5,946.30 | |||
Accounts payable | (9,604.8 | ) | ||
Accrued liabilities | (2,008.8 | ) | ||
Bank loans | (15,133.5 | ) | ||
Notes payable | (6,599.3 | ) | ||
Other liabilities | (9,166.8 | ) | ||
Amount due related party | (7,859.7 | ) | ||
$ | 27,216.70 | |||
Loss on exit of segment | $ | (3,416.4 | ) | |
Regenerative Medicine - China segment [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands): | |||
Cash | $ | 195.1 | ||
Prepaid expenses and other current assets | 14.9 | |||
Property, plant and equipment, net | 1,023.70 | |||
Other Assets | 330.5 | |||
Accounts payable | (177.1 | ) | ||
Accrued liabilities | (79.2 | ) | ||
Accumulated comprehensive income | (169.9 | ) | ||
Loss on exit of segment | $ | 1,138.00 | ||
Year Ended December 31, | ||||
2012 | ||||
Revenue | $ | 52.3 | ||
Cost of revenues | (30.6 | ) | ||
Research and development | (103.3 | ) | ||
Selling, general, and administrative | (497.3 | ) | ||
Other income (expense) | (6.8 | ) | ||
Loss on exit of segment | (1,138.0 | ) | ||
Loss from discontinued operations | $ | (1,723.7 | ) | |
Pharmaceutical Manufacturing - China business [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | ||||
Year Ended December 31, | ||||
2012 | ||||
Revenue | $ | 61,703.10 | ||
Cost of revenues | (40,245.2 | ) | ||
Research and development | (1,836.4 | ) | ||
Selling, general, and administrative | (10,740.0 | ) | ||
Other expense | (1,045.2 | ) | ||
Provision for income taxes | (1,794.1 | ) | ||
Asset impairments | (31,170.1 | ) | ||
Loss on sale of segment | (3,416.4 | ) | ||
Loss from discontinued operations | $ | (28,544.3 | ) |
Discontinued_Operations_Fair_v
Discontinued Operations Fair value of discontinued operations (Tables) | 12 Months Ended | |||
Dec. 31, 2014 | ||||
Discontinued Operations and Disposal Groups [Abstract] | ||||
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet. The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands): | |||
Fair value of consideration received | $ | 13,397.90 | ||
Carrying value of segment non-controlling interest | 6,015.00 | |||
Carrying value of segment accumulated comprehensive income | 4,387.40 | |||
$ | 23,800.30 | |||
Less carrying amount of assets and liabilities sold: | ||||
Cash | $ | 8,457.50 | ||
Restricted Cash | 2,918.10 | |||
Accounts Receivable | 6,130.20 | |||
Inventories | 15,077.70 | |||
Prepaid expenses and other current assets | 957.8 | |||
Property, plant and equipment, net | 38,102.00 | |||
Other assets | 5,946.30 | |||
Accounts payable | (9,604.8 | ) | ||
Accrued liabilities | (2,008.8 | ) | ||
Bank loans | (15,133.5 | ) | ||
Notes payable | (6,599.3 | ) | ||
Other liabilities | (9,166.8 | ) | ||
Amount due related party | (7,859.7 | ) | ||
$ | 27,216.70 | |||
Loss on exit of segment | $ | (3,416.4 | ) |
Commitments_and_Contingencies_
Commitments and Contingencies (Tables) | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
Commitments and Contingencies [Abstract] | |||||
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2014 are as follows (in thousands): | ||||
Years ended | Operating Leases | ||||
2015 | $ | 1,567.90 | |||
2016 | 1,656.90 | ||||
2017 | 1,367.30 | ||||
2018 | 535.2 | ||||
2019 | 492.4 | ||||
2020 and thereafter | 628.1 | ||||
Total minimum lease payments | $ | 6,247.80 | |||
Equity_Plan_Tables
Equity Plan (Tables) | 12 Months Ended | ||||||
Dec. 31, 2014 | |||||||
Statement of Stockholders' Equity [Abstract] | |||||||
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] | The number of remaining shares authorized to be issued under the various equity plans are as follows: | ||||||
2003 Equity Plan | 2009 Equity Plan | ||||||
Shares Authorized for Issuance | 250,000 | 8,995,000 | |||||
Outstanding Stock Options | (122,395 | ) | (4,304,881 | ) | |||
Exercised Stock Options | (9,250 | ) | (80,856 | ) | |||
Restricted stock or equity grants issued under Equity Plans | (88,993 | ) | (946,711 | ) | |||
Shares Expired | (29,362 | ) | — | ||||
Total common shares remaining to be issued under the Equity Plans | — | 3,662,552 | |||||
AvailableforSaleSecurities_Tab
Available-for-Sale-Securities (Tables) | 12 Months Ended | |||||||||||||||
Dec. 31, 2014 | ||||||||||||||||
Available-for-sale Securities [Abstract] | ||||||||||||||||
Schedule of Available-for-sale Securities Reconciliation [Table Text Block] | The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands): | |||||||||||||||
December 31, 2014 | ||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | |||||||||||||
Certificate of deposits | $ | 249 | $ | — | $ | — | $ | 249 | ||||||||
Money market funds | 12,791.90 | — | — | 12,791.90 | ||||||||||||
Municipal debt securities | 9,317.30 | 1.3 | — | 9,318.60 | ||||||||||||
Total | $ | 22,358.20 | $ | 1.3 | $ | — | $ | 22,359.50 | ||||||||
Marketable Securities [Table Text Block] | Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands): | |||||||||||||||
December 31, 2014 | ||||||||||||||||
Cash and cash equivalents | $ | 15,279.40 | ||||||||||||||
Marketable securities | 7,080.10 | |||||||||||||||
Total | $ | 22,359.50 | ||||||||||||||
Quarterly_Financial_Data_Table
Quarterly Financial Data (Tables) | 12 Months Ended | |||||||||||||||||||||||||||||||
Dec. 31, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ||||||||||||||||||||||||||||||||
Schedule of Quarterly Financial Information [Table Text Block] | respectively. | |||||||||||||||||||||||||||||||
Three Months Ended | ||||||||||||||||||||||||||||||||
(in thousands, except per share data) | March 31, 2013 | June 30, 2013 | September 30, 2013 | December 31, 2013 | ||||||||||||||||||||||||||||
Three Months Ended | Revenues | $ | 2,524 | $ | 4,359 | $ | 3,707 | $ | 4,078 | |||||||||||||||||||||||
(in thousands, except per share data) | March 31, 2014 | June 30, 2014 | September 30, 2014 | December 31, 2014 | ||||||||||||||||||||||||||||
Revenues | $ | 4,056 | $ | 4,489 | $ | 4,118 | $ | 5,276 | Total operating costs and expenses | $ | 11,355 | $ | 12,530 | $ | 13,020 | $ | 14,573 | |||||||||||||||
Total operating costs and expenses | $ | 17,555 | $ | 16,919 | $ | 20,376 | $ | 20,830 | Net loss from continuing operations | $ | (8,864 | ) | $ | (8,626 | ) | $ | (9,277 | ) | $ | (12,719 | ) | |||||||||||
Net loss attributable to NeoStem, Inc. common stockholders | $ | (8,801 | ) | $ | (8,575 | ) | $ | (9,071 | ) | $ | (12,535 | ) | ||||||||||||||||||||
Net loss from continuing operations | $ | (13,830 | ) | $ | (12,769 | ) | $ | (17,177 | ) | $ | (11,691 | ) | Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders | $ | (0.53 | ) | $ | (0.46 | ) | $ | (0.45 | ) | $ | (0.47 | ) | |||||||
Net loss attributable to NeoStem, Inc. common stockholders | $ | (13,682 | ) | $ | (12,605 | ) | $ | (16,974 | ) | $ | (11,612 | ) | ||||||||||||||||||||
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders | $ | (0.49 | ) | $ | (0.40 | ) | $ | (0.48 | ) | $ | (0.32 | ) |
The_Business_Details
The Business (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Subsidiary or Equity Method Investee [Line Items] | ||
Change in Ownership in Subsidiary | $0 | $0 |
NeoStem, Inc. [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 100.00% | |
Location [Member] | NeoStem, Inc. [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Entity Location | United States of America | |
Location [Member] | NeoStem Therapies, Inc [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Entity Location | United States of America | |
Location [Member] | Stem Cell Technologies, Inc [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Entity Location | United States of America | |
Location [Member] | Amorcyte, LLC [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Entity Location | United States of America | |
Location [Member] | Progenitor Cell Therapy, LLC [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Entity Location | United States of America | |
Location [Member] | NeoStem Family Storage, LLC [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Entity Location | United States of America | |
Location [Member] | Athelos Corporation [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Entity Location | United States of America | |
Location [Member] | PCT Allendale, LLC [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Entity Location | United States of America | |
UNITED STATES | NeoStem Therapies, Inc [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 100.00% | |
UNITED STATES | Stem Cell Technologies, Inc [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 100.00% | |
UNITED STATES | Amorcyte, LLC [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 100.00% | |
UNITED STATES | Progenitor Cell Therapy, LLC [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 100.00% | |
UNITED STATES | NeoStem Family Storage, LLC [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 100.00% | |
UNITED STATES | Athelos Corporation [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 96.20% | |
UNITED STATES | PCT Allendale, LLC [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 100.00% | |
UNITED STATES | NeoStem Oncology [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Subsidiary, Ownership Interest by Parent | 100.00% | |
Entity Location | United States of America | |
Noncontrolling Interest [Member] | ||
Subsidiary or Equity Method Investee [Line Items] | ||
Change in Ownership in Subsidiary | $700,000 |
Summary_of_Significant_Account2
Summary of Significant Accounting Policies (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Property, Plant and Equipment [Line Items] | |||
Concentration Risk, Percentage | 0.00% | ||
Issuance Of Common Stock In Connection With Preferred Stock Settlement Value | $674,194 | ||
Clinical Services Reimbursement | $3,700,000 | $2,100,000 | $3,500,000 |
Revene Recognition Period for Cryoperservation Process | 24 hours | ||
Building and Building Improvements [Member] | Minimum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P25Y | ||
Building and Building Improvements [Member] | Maximum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P30Y | ||
Machinery and Equipment [Member] | Minimum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P8Y | ||
Machinery and Equipment [Member] | Maximum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P12Y | ||
Lab Equipment [Member] | Minimum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P5Y | ||
Lab Equipment [Member] | Maximum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P7Y | ||
Furniture and Fixtures [Member] | Minimum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P5Y | ||
Furniture and Fixtures [Member] | Maximum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P12Y | ||
Computer Software, Intangible Asset [Member] | Minimum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P3Y | ||
Computer Software, Intangible Asset [Member] | Maximum [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | P5Y | ||
Leasehold Improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Estimated Useful Lives | life of lease | ||
NeoStem, Inc. [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Concentration Risk, Percentage | 0.00% |
Acquisitions_Fair_value_of_ass
Acquisitions Fair value of assets acquired and liabilities (Details) (USD $) | 3 Months Ended | 8 Months Ended | 12 Months Ended | ||||||||||
Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | 8-May-14 | |
Business Acquisition [Line Items] | |||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | $51,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 1,041,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other | 201,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent | 13,901,000 | ||||||||||||
Common Stock, Shares, Issued | 5,329,593 | ||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 90,000,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 19,400,000 | ||||||||||||
Business Acquisition, Transaction Costs | 33,500,000 | ||||||||||||
Goodwill | 25,209,336 | 11,117,770 | 25,209,336 | 25,209,336 | 11,117,770 | 14,092,000 | |||||||
Equity Issued in Business Combination, Fair Value Disclosure | 21,600,000 | ||||||||||||
Business Combination, Contingent Consideration, Liability | 18,260,000 | 9,450,000 | 18,260,000 | 18,260,000 | 9,450,000 | 11,900,000 | |||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 40,000 | ||||||||||||
Business Acquisition, Pro Forma Net Income (Loss) | -7,600,000 | ||||||||||||
NeoStem, Inc. common stockholders | ($0.32) | ($0.48) | ($0.40) | ($0.49) | ($0.47) | ($0.45) | ($0.46) | ($0.53) | ($1.68) | ($1.90) | ($4) | ||
Business Combination, Acquired Receivables, Fair Value | 45,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets | 19,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill | 34,290,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | 333,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | 2,014,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net | $33,491,000 |
Acquisitions_CSC_acquisitions_
Acquisitions CSC acquisitions (Details) (USD $) | 3 Months Ended | 8 Months Ended | 12 Months Ended | ||||||||||
Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | 8-May-14 | |
Business Acquisition [Line Items] | |||||||||||||
Revenues | $5,276 | $4,118 | $4,489 | $4,056 | $4,078 | $3,707 | $4,359 | $2,524 | $17,938,790 | $14,668,455 | $14,329,889 | ||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 40,000 | ||||||||||||
Common Stock, Shares, Issued | 5,329,593 | ||||||||||||
Business Acquisition, Transaction Costs | 33,500,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | 51,000 | ||||||||||||
Business Combination, Acquired Receivables, Fair Value | 45,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets | 19,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 1,041,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other | 201,000 | ||||||||||||
Goodwill | 25,209,336 | 11,117,770 | 25,209,336 | 25,209,336 | 11,117,770 | 14,092,000 | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill | 34,290,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | 333,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | 2,014,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent | 13,901,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net | 33,491,000 | ||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 90,000,000 | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 19,400,000 | ||||||||||||
Equity Issued in Business Combination, Fair Value Disclosure | 21,600,000 | ||||||||||||
Business Combination, Contingent Consideration, Liability | 18,260,000 | 9,450,000 | 18,260,000 | 18,260,000 | 9,450,000 | 11,900,000 | |||||||
Business Acquisition, Pro Forma Net Income (Loss) | -7,600,000 | ||||||||||||
NeoStem, Inc. common stockholders | ($0.32) | ($0.48) | ($0.40) | ($0.49) | ($0.47) | ($0.45) | ($0.46) | ($0.53) | ($1.68) | ($1.90) | ($4) | ||
Net loss | -55,466,246 | -39,485,334 | -66,369,311 | ||||||||||
Net Income (Loss) Attributable to Parent | -11,612 | -16,974 | -12,605 | -13,682 | -12,535 | -9,071 | -8,575 | -8,801 | -54,872,933 | -38,981,244 | -53,769,484 | ||
NeoStem, Inc. [Member] | |||||||||||||
Business Acquisition [Line Items] | |||||||||||||
Revenues | 17,939,000 | 14,668,000 | |||||||||||
NeoStem, Inc. common stockholders | ($1.68) | ($1.90) | |||||||||||
Net loss | -55,467,000 | -39,485,000 | |||||||||||
Net Income (Loss) Attributable to Parent | -54,873,000 | -38,981,000 | |||||||||||
NeoStem Oncology [Member] | |||||||||||||
Business Acquisition [Line Items] | |||||||||||||
Business Acquisition, Pro Forma Revenue | 18,649,000 | 15,471,000 | |||||||||||
Business Acquisition, Pro Forma Net Income (Loss) | -57,964,000 | -44,790,000 | |||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | ($57,371,000) | ($44,286,000) | |||||||||||
Business Acquisition, Pro Forma Earnings Per Share, Diluted | ($1.51) | ($1.71) |
AvailabeforSaleSecurities_Avai1
Availabe-for-Sale-Securities Available-for-Sale-Securities (Details) (USD $) | Dec. 31, 2014 | Sep. 30, 2014 |
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale Securities, Amortized Cost Basis | $22,358,200 | |
Gross Unrealized Gains | 1,300 | |
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value | 0 | |
Fair Value, Estimate Not Practicable, Investments | 22,359,500 | |
Cash and cash equivalents | 15,279,400 | |
Available-for-sale Securities, Current | 7,080,100 | |
Cash, Cash Equivalents, and Short-term Investments | 22,359,500 | |
Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Amortized Cost Basis | 22,358,200 | 22,358,200 |
Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value | 22,359,500 | |
Available-for-sale Securities, Debt Securities | 22,359,500 | |
Municipal Bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale Securities, Amortized Cost Basis | 9,317,300 | |
Gross Unrealized Gains | 1,300 | |
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value | 0 | |
Fair Value, Estimate Not Practicable, Investments | 9,318,600 | |
Money Market Funds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale Securities, Amortized Cost Basis | 12,791,900 | |
Gross Unrealized Gains | 0 | |
Money Market Funds, at Carrying Value | 12,791,900 | |
Certificates of Deposit [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available-for-sale Securities, Amortized Cost Basis | 249,000 | |
Gross Unrealized Gains | 0 | |
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value | 0 | |
Fair Value, Estimate Not Practicable, Investments | $249,000 |
Deferred_Costs_Details
Deferred Costs (Details) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Schedule of Inventory [Line Items] | ||
Deferred Costs | $2,566,989 | $1,270,223 |
Multiple Stage Contracts [Member] | ||
Schedule of Inventory [Line Items] | ||
Deferred Revenue | $3,900,000 | $1,500,000 |
Property_Plant_Equipment_Detai
Property, Plant & Equipment (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Property, Plant and Equipment [Line Items] | |||
Buildings and Improvements, Gross | $11,298,700 | $11,229,900 | |
Depreciation, Depletion and Amortization | 1,600,000 | 1,000,000 | 1,000,000 |
Property, plant and equipment, net | 15,960,731 | 12,844,216 | |
Machinery and Equipment, Gross | 68,300 | 58,200 | |
Property, Plant and Equipment, Other, Gross | 6,324,700 | 2,743,700 | |
Furniture and Fixtures, Gross | 1,166,300 | 958,000 | |
Capitalized Computer Software, Gross | 312,400 | 203,100 | |
Leasehold Improvements, Gross | 2,219,600 | 674,100 | |
Property, Plant and Equipment, Gross | 21,390,000 | 15,867,000 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | -5,429,300 | -3,022,800 | |
Property, Plant and Equipment, Other Types [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, net | $15,960,700 | $12,844,200 |
Loss_Per_Share_Details
Loss Per Share (Details) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Stock Options [Member] | |||
Class of Stock [Line Items] | |||
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares | 4,427,276 | 2,932,191 | 2,168,668 |
Warrant [Member] | |||
Class of Stock [Line Items] | |||
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares | 3,550,956 | 4,898,266 | 5,528,761 |
Restricted Stock [Member] | |||
Class of Stock [Line Items] | |||
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares | 280,481 | 78,500 | 34,250 |
Fair_Value_Measurements_Fair_v
Fair Value Measurements Fair value hierarchy the Companybs financial assets and liabilities (Details) (USD $) | Dec. 31, 2014 | 8-May-14 | Dec. 31, 2013 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $90,000,000 | ||
Business Combination, Contingent Consideration, Liability | $18,260,000 | $11,900,000 | $9,450,000 |
Fair_Value_Measurements_Financ
Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) (USD $) | 12 Months Ended | |||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | 8-May-14 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Warrant Derivative Liabilities | $0 | $23,200 | ||
Business Combination, Contingent Consideration, Liability | 18,260,000 | 9,450,000 | 11,900,000 | |
Fair Value, Net Asset (Liability) | 18,260,000 | 9,473,200 | ||
Changes in acquisition-related contingent consideration | 11,890,000 | |||
Changes in acquisition-related contingent consideration | -3,080,000 | 1,900,000 | 4,420,000 | |
Change in warrant liabilities | -23,200 | |||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances | 9,473,200 | |||
Fair Value, Inputs, Level 2 [Member] | ||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Available-for-sale Securities | 7,080,000 | |||
Fair Value, Inputs, Level 3 [Member] | ||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Warrant Derivative Liabilities | 23,200 | |||
Business Combination, Contingent Consideration, Liability | 18,260,000 | 9,450,000 | ||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances | $9,473,200 |
Goodwill_and_Other_Intangible_2
Goodwill and Other Intangible Assets Goodwill (Details) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Goodwill [Line Items] | ||
Future Amortization Expense, Year One | $605,200 | |
Future Amortization Expense, Year Two | 605,200 | |
Future Amortization Expense, Year Three | 605,200 | |
Future Amortization Expense, Year Four | 605,200 | |
Future Amortization Expense, Year Five | 605,200 | |
Future Amortization Expense, after Year Five | 44,534,400 | |
Finite-Lived Intangible Assets, Net | $47,560,400 | $13,875,600 |
Goodwill_and_Other_Intangible_3
Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Assets, Gross | $50,059,000 | $15,769,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | -2,498,600 | -1,893,400 |
Finite-Lived Intangible Assets, Net | 47,560,400 | 13,875,600 |
Customer Lists [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Assets, Gross | 1,000,000 | 1,000,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | -395,100 | -295,100 |
Finite-Lived Intangible Assets, Net | 604,900 | 704,900 |
Finite-Lived Intangible Assets, Useful Life | 10 years | |
Manufacturing Technology [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Assets, Gross | 3,900,000 | 3,900,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | -1,540,900 | -1,150,900 |
Finite-Lived Intangible Assets, Net | 2,359,100 | 2,749,100 |
Finite-Lived Intangible Assets, Useful Life | 10 years | |
Trade Names [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Assets, Gross | 800,000 | 800,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | -316,100 | -236,100 |
Finite-Lived Intangible Assets, Net | 483,900 | 563,900 |
Finite-Lived Intangible Assets, Useful Life | 10 years | |
In Process R&D [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Assets, Gross | 43,690,000 | 9,400,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | 0 | 0 |
Finite-Lived Intangible Assets, Net | 43,690,000 | 9,400,000 |
Finite Lived Intangible Assets, Useful Life [String] | Indefinite | |
VSEL Patent Rights [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Assets, Gross | 669,000 | 669,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | -246,500 | -211,300 |
Finite-Lived Intangible Assets, Net | $422,500 | $457,700 |
Finite-Lived Intangible Assets, Useful Life | 19 years |
Goodwill_and_Other_Intangible_4
Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Intangible Asset Amortization Expense By Category [Line Items] | |||
Amortization of Intangible Assets | $605,200 | $605,200 | $605,200 |
Cost of Sales [Member] | |||
Intangible Asset Amortization Expense By Category [Line Items] | |||
Amortization of Intangible Assets | 316,800 | 390,000 | 390,000 |
General and Administrative Expense [Member] | |||
Intangible Asset Amortization Expense By Category [Line Items] | |||
Amortization of Intangible Assets | 180,000 | 180,000 | 180,000 |
Research and Development Expense [Member] | |||
Intangible Asset Amortization Expense By Category [Line Items] | |||
Amortization of Intangible Assets | $108,400 | $35,200 | $35,200 |
Accrued_Liabilities_Accrued_Li1
Accrued Liabilities Accrued Liabilities (Details) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Accrued Liabilities [Abstract] | ||
Employee-related Liabilities | $2,807.20 | $2,325.80 |
Accrued Professional Fees | 495.4 | 544.8 |
Accrued Royalties, Current | 0 | 500 |
Other Accrued Liabilities | 1,020.30 | 647.4 |
Accrued Liabilities | $4,322.90 | $4,018 |
Debt_Details
Debt (Details) (USD $) | 12 Months Ended | 0 Months Ended | |||
Dec. 31, 2014 | Oct. 31, 2007 | Dec. 06, 2010 | Sep. 26, 2014 | Dec. 31, 2013 | |
Debt Instrument [Line Items] | |||||
Debt Instrument, Annual Principal Payment | $19,200,000 | ||||
Interest Expense, Long-term Debt | 300,000 | ||||
Notes Payable | 1,600,000 | 900,000 | |||
Secured Long-term Debt, Noncurrent | 20,000,000 | ||||
Debt Instrument, Periodic Payment | 10,000,000 | ||||
Mortgage Loans on Real Estate, Carrying Amount of Mortgages | 3,100,000 | ||||
Proceeds from Issuance of Debt | 11,300,000 | ||||
Debt issuance costs | 100,000 | ||||
Payment Guarantee [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Periodic Payment, Interest | 8.00% | ||||
Long-term Debt [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum | 8.50% | ||||
Convertible Notes Payable [Member] | |||||
Debt Instrument [Line Items] | |||||
Purchase of condominium units | 3,800,000 | ||||
Debt Instrument, Periodic Payment, Interest | 5.00% | ||||
Mortgage Loans on Real Estate, Carrying Amount of Mortgages | 2,500,000 | ||||
Mortgage Loans on Real Estate, New Mortgage Loans | 3,100,000 | ||||
NeoStem, Inc. [Member] | Long-term Debt [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Period of Loan | 36 months | ||||
Debt Instrument, Term | 30 months | ||||
PCT Allendale, LLC [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Periodic Payment | 20,766 | ||||
PCT Allendale, LLC [Member] | Convertible Notes Payable [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Period of Loan | 124 months | ||||
Debt Instrument, Periodic Payment, Interest | 6.00% | ||||
Debt Instrument, Period of Fixed Interest Rate | 64 months | ||||
Mortgage Loans on Real Estate, Carrying Amount of Mortgages | 763,000 | ||||
Mortgage Loans on Real Estate, New Mortgage Loans | 1,000,000 | ||||
Long-term Debt [Member] | |||||
Debt Instrument [Line Items] | |||||
Long-term Debt, Gross | 15,000,000 | ||||
License Agreement Terms [Member] | |||||
Debt Instrument [Line Items] | |||||
Long-term Debt, Gross | 5,000,000 | ||||
Less than one year [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Annual Principal Payment | 2,400,000 | ||||
Debt Instrument, Redemption, Period Two [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Annual Principal Payment | 5,700,000 | ||||
Debt Instrument, Redemption, Period Three [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Annual Principal Payment | 5,700,000 | ||||
Debt Instrument, Redemption, Period Four [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt Instrument, Annual Principal Payment | $5,400,000 |
Preferred_Stock_Convertible_Re
Preferred Stock Convertible Redeemable Series E Preferred Stock (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Class of Stock [Line Items] | |||
Net proceeds from issuance of capital stock | $16,710,645 | $58,736,165 | $16,428,827 |
Shareholders_Equity_Details
Shareholders' Equity (Details) (USD $) | 12 Months Ended | ||||||||||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2014 | Sep. 28, 2011 | Oct. 10, 2012 | Oct. 14, 2011 | Jan. 18, 2011 | Jun. 02, 2010 | Oct. 29, 2009 | 9-May-09 | |
Class of Stock [Line Items] | |||||||||||
weighted average estimated fair value of restricted stock | $5.44 | $6.53 | |||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 917,907 | 514,700 | |||||||||
Proceeds from Warrant Exercises | $1,720,725 | $3,028,241 | $6,604,418 | ||||||||
Stock Issued During Period, Value, Warrant Inducements | 62,014 | 228,676 | |||||||||
Warrant inducements | 0 | 40,407 | |||||||||
Stock Issued During Period, Value, Restricted Stock Award, Gross | 4,996,300 | 3,360,000 | |||||||||
Common Stock [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Stock Issued During Period, Shares, New Issues | 2,959,214 | 9,712,724 | 3,573,229 | ||||||||
Stock Issued During Period, Value, Warrant Inducements | 0 | 146 | |||||||||
Warrant inducements | 0 | 145,895.20 | |||||||||
Warrant holder A [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 333,250 | ||||||||||
Proceeds from Issuance of Warrants | 1,700,000 | ||||||||||
Aspire Capital Purchase Agreement [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Committment Value Under Purchase Agreement | $20,000,000 | $20,000,000 | |||||||||
Term Of Agreement In Months | 24 | 24 | |||||||||
Discount Applied To Weighted Average Price | 5.00% | ||||||||||
Non US Equity Plan [Member] | Stock Options [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Common Stock, Shares Authorized | 570,000 | ||||||||||
2009 Equity Plan [Member] | Stock Options [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Common Stock, Shares Authorized | 8,995,000 | 5,995,000 | 450,000 | 2,375,000 | 1,775,000 | 1,375,000 | 975,000 | 380,000 |
Shareholders_Equity_Components
Shareholders' Equity Components of share-based compensation expense (Details) (USD $) | 12 Months Ended | ||||||||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 10, 2012 | Oct. 14, 2011 | Jan. 18, 2011 | Jun. 02, 2010 | Oct. 29, 2009 | 9-May-09 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | -3,543,456 | ||||||||
Share-based Compensation Expense | $11,209,500 | $6,838,700 | $6,712,500 | ||||||
Cost of Sales [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Share-based Compensation Expense | 494,200 | 314,000 | 195,000 | ||||||
Research and Development Expense [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Share-based Compensation Expense | 2,058,200 | 822,200 | 432,900 | ||||||
General and Administrative Expense [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Share-based Compensation Expense | $8,657,100 | $5,702,500 | $6,084,600 | ||||||
Stock Options [Member] | 2009 Equity Plan [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Common Stock, Shares Authorized | 8,995,000 | 5,995,000 | 450,000 | 2,375,000 | 1,775,000 | 1,375,000 | 975,000 | 380,000 | |
Stock Options [Member] | Non US Equity Plan [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Common Stock, Shares Authorized | 570,000 | ||||||||
2009 Equity Plan [Member] | US Equity Plan [Member] | Stock Options [Member] | 2009 Equity Plan [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | -80,856 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | -946,711 | ||||||||
Shares Expired | 0 | ||||||||
Common Stock, Shares Authorized | 8,995,000 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | -4,304,881 | ||||||||
Common Stock, Shares, Outstanding | -3,662,552 | ||||||||
2003 Equity Plan [Member] | US Equity Plan [Member] | Stock Options [Member] | 2003 Equity Plan [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | -9,250 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | -88,993 | ||||||||
Shares Expired | -29,362 | ||||||||
Common Stock, Shares Authorized | 250,000 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | -122,395 | ||||||||
Common Stock, Shares, Outstanding | 0 |
Shareholders_Equity_Activity_f
Shareholders' Equity Activity for stock options and warrants (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $28,600 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | 16,600 | 1,658,100 | |
Common Stock Warrants, Shares | 4,898,266 | ||
Weighted Average Exercise Price, Warrants Outstanding | 14.12 | 16.5 | |
Weighted Average Remaining Contractual Term warrant outstanding | 2 years 1 month 13 days | ||
Weighted Average Remaining Contractual Term, Warrants Outstanding | 2 years 7 months 17 days | ||
Aggregate Intrinsic Value, Warrants Outstanding | 1,000 | 1,811,000 | |
Warrant inducements | 0 | 40,407 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward] | |||
Warrants Granted | 2,722 | ||
Weighted Average Exercise Price, Warrants Granted | $12.26 | ||
Warrants Exercised | -333,250 | ||
Weighted Average Exercise Price, Warrants Exercised | $5.16 | ||
Warrants Expired | -100,108 | ||
Weighted Average Exercise Price, Warrants Expired | $70 | ||
Warrants Canceled | -916,674 | ||
Weighted Average Exercise Price, Warrants Canceled | $23.95 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | 27,000 | ||
shares, vested and expected to vest | 3,550,956 | ||
Weighted Average Exercise Price, Warrants vested & expected to vest | 14.12 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 3,543,456 | ||
Weighted Average Exercise Price, Warrants Exercisable | 14.13 | ||
weighted Average Remaining Contractual Term, warrants vested | 2 years 1 month 13 days | ||
Aggregate Intrinsic Value, Warrants vested and expected to vest | 1,000 | ||
Aggregate Intrinsic Value, Warrants vested | 1,000 | ||
Warrants Issued During Period, Value | $0 | $149,900 | |
Warrant [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $0 | $3.71 | $4.10 |
US Equity Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $9.19 | $11.19 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 6 years 11 months 5 days | 6 years 9 months 22 days | |
Common Stock, Shares, Outstanding | 3,550,956 | ||
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest | 2 years 1 month 13 days | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 4,253,465 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $9.28 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term | 6 years 10 months 2 days | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | 2,265,850 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $6.72 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward] | |||
Stock Options, Outstanding at December 31, 2011 | 2,932,191 | ||
Stock Options Exercised | -48,987 | ||
Stock Options Forfeited | -353,116 | ||
Stock Options Expired | -368,704 | ||
Stock Options, Outstanding at September 30, 2012 | 4,427,234 | 2,932,191 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | $12.94 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $6.78 | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $5.53 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | 2,968,379 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $10.22 | ||
Options, Vested, weighted Average Remaining Contractual Term | 6 years 1 month 10 days |
Shareholders_Equity_Total_comp
Shareholders' Equity Total compensation cost related to nonvested awards (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 917,907 | 514,700 |
weighted average estimated fair value of restricted stock | $5.44 | $6.53 |
Stock Issued During Period, Value, Restricted Stock Award, Gross | $4,996,300 | $3,360,000 |
Restricted Stock [Member] | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Unrecognized compensation cost | 528,600 | |
Excepted weighted-average period in years of compensation cost to be recognized | 0 years 3 months 22 days | |
Warrant [Member] | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Unrecognized compensation cost | 7,200 | |
Excepted weighted-average period in years of compensation cost to be recognized | 0 years 6 months 15 days | |
Stock Option [Member] | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Unrecognized compensation cost | $4,598,400 | |
Excepted weighted-average period in years of compensation cost to be recognized | 3 years 9 months 15 days |
Shareholders_Equity_Equity_Iss
Shareholders' Equity Equity Issuances (Details) (USD $) | 12 Months Ended | 3 Months Ended | |||||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2014 | 8-May-14 | Sep. 28, 2011 | Feb. 28, 2013 | |
Class of Stock [Line Items] | |||||||
Warrant inducements | 0 | 40,407 | |||||
Common Stock, Shares, Issued | 5,329,593 | ||||||
Proceeds from issuance of common stock | $16,710,645 | $58,736,166 | $16,428,827 | ||||
Aspire Capital Purchase Agreement [Member] | |||||||
Class of Stock [Line Items] | |||||||
Committment Value Under Purchase Agreement | 20,000,000 | 20,000,000 | |||||
Proceeds from Issuance of Common Stock | 5,600,000 | ||||||
Term Of Agreement In Months | 24 | 24 | |||||
Discount Applied To Weighted Average Price | 5.00% | ||||||
Proceeds from issuance of common stock | 10,900,000 | ||||||
Purchase Commitment, Remaining Minimum Amount Committed | 19,100,000 | ||||||
Aspire Capital Purchase Agreement [Member] | |||||||
Class of Stock [Line Items] | |||||||
Stock Issued During Period, Shares, New Issues | 800,000 | ||||||
Common Stock, Shares, Issued | 150,000 | 1,600,000 | |||||
Purchase Commitment, Remaining Minimum Amount Committed | $30,000,000 |
Shareholders_Equity_Warrants_D
Shareholders' Equity Warrants (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Class of Warrant or Right [Line Items] | ||
Weighted Average Exercise Price, Warrants Exercised | $5.16 | |
Warrants Issued During Period, Value | $0 | $149,900 |
Warrant inducements | 0 | 40,407 |
Warrant holder A [Member] | ||
Class of Warrant or Right [Line Items] | ||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 333,250 | |
Proceeds from Issuance of Warrants | $1,700,000 |
Shareholders_Equity_Equity_Pla
Shareholders' Equity Equity Plan (Details) (USD $) | 12 Months Ended | |||||||
Dec. 31, 2014 | Dec. 31, 2013 | Oct. 10, 2012 | Oct. 14, 2011 | Jan. 18, 2011 | Jun. 02, 2010 | Oct. 29, 2009 | 9-May-09 | |
Stock Options [Member] | 2009 Equity Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Common Stock, Shares Authorized | 8,995,000 | 5,995,000 | 450,000 | 2,375,000 | 1,775,000 | 1,375,000 | 975,000 | 380,000 |
Stock Options [Member] | Non US Equity Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Common Stock, Shares Authorized | 570,000 | |||||||
ESPP [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Common Stock, Shares Authorized | 500,000 | |||||||
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate | 15.00% | |||||||
ESPP annual cap | $25,000 | |||||||
percentage of stock closing price | 85.00% | |||||||
percentage of ESPP closing price | 85.00% | |||||||
Shares, Issued | 65,441 | |||||||
Shares, Outstanding | 434,559 |
Shareholders_Equity_Options_De
Shareholders' Equity Options (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Class of Stock [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 48,987 | ||
Proceeds from exercise of options | $271,008 | $150,658 | $0 |
Maximum [Member] | |||
Class of Stock [Line Items] | |||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | $6.20 | ||
Minimum [Member] | |||
Class of Stock [Line Items] | |||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | $5.20 |
ShareBased_Compensation_Detail
Share-Based Compensation (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Stock Option [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $4,598,400 |
Excepted weighted-average period in years of compensation cost to be recognized | 3 years 9 months 15 days |
Warrant [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | 7,200 |
Excepted weighted-average period in years of compensation cost to be recognized | 0 years 6 months 15 days |
Restricted Stock [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $528,600 |
Excepted weighted-average period in years of compensation cost to be recognized | 0 years 3 months 22 days |
ShareBased_Compensation_ShareB
Share-Based Compensation Share-Based Compensation (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Allocated Share-based Compensation Expense | $11,209,500 | $6,838,700 | $6,712,500 |
Cost of Sales [Member] | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Allocated Share-based Compensation Expense | 494,200 | 314,000 | 195,000 |
Research and Development Expense [Member] | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Allocated Share-based Compensation Expense | 2,058,200 | 822,200 | 432,900 |
General and Administrative Expense [Member] | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Allocated Share-based Compensation Expense | 8,657,100 | 5,702,500 | 6,084,600 |
Warrant [Member] | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition | 9,600 | 129,000 | 171,600 |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 66.00% | 73.00% | 76.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 66.00% | 79.00% | 83.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 0.79% | 0.32% | 0.27% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 0.79% | 1.73% | 0.88% |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $0 | $3.71 | $4.10 |
Stock Options [Member] | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $4.56 | $4.29 | $3.63 |
Stock Option [Member] | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition | $5,387,100 | $3,375,700 | $5,408,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 62.00% | 61.00% | 73.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 77.00% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 0.12% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 3.00% | 0.00% | 0.00% |
ShareBased_Compensation_Valuat
Share-Based Compensation Valuation Assumptions (Details) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Stock Option [Member] | |||
Class of Stock [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 62.00% | 61.00% | 73.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 77.00% | 0.00% | 0.00% |
Fair Value Assumptions, Weighted Average Volatility Rate | 74.00% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 0.12% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 3.00% | 0.00% | 0.00% |
Warrant [Member] | |||
Class of Stock [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 66.00% | 73.00% | 76.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 66.00% | 79.00% | 83.00% |
Fair Value Assumptions, Weighted Average Volatility Rate | 0.00% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 0.79% | 0.32% | 0.27% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 0.79% | 1.73% | 0.88% |
Minimum [Member] | Stock Option [Member] | |||
Class of Stock [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum | 0 years | 1 year | 2 years |
Minimum [Member] | Warrant [Member] | |||
Class of Stock [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum | 3 years | 2 years | 2 years |
Maximum [Member] | Stock Option [Member] | |||
Class of Stock [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum | 10 years | 10 years | 10 years |
Maximum [Member] | Warrant [Member] | |||
Class of Stock [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum | 3 years | 5 years | 5 years |
Income_Taxes_Details
Income Taxes (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Income Tax Examination [Line Items] | |||
Current Federal Tax Expense (Benefit) | $0 | $0 | $0 |
Deferred State and Local Income Tax Expense (Benefit) | -263,200 | 303,200 | -175,500 |
Federal Income Tax Expense (Benefit), Continuing Operations | 159,000 | 476,900 | 0 |
State and Local Income Tax Expense (Benefit), Continuing Operations | -263,200 | 303,200 | -175,500 |
Deferred Federal Income Tax Expense (Benefit) | 159,000 | 476,900 | 0 |
Current State and Local Tax Expense (Benefit) | 0 | 0 | 0 |
Current Income Tax Expense (Benefit) | 0 | 0 | 0 |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate | 34.00% | ||
Operating Loss Carryforwards | 177,200,000 | 110,600,000 | |
Deferred income taxes | -104,200 | 780,100 | -175,500 |
Income Tax Expense (Benefit) | -104,202 | 780,104 | -175,533 |
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate | -18,894,000 | -13,159,800 | -12,334,100 |
Income Tax Reconciliation, State and Local Income Taxes | -3,435,000 | -3,430,900 | -2,154,100 |
Permanent non deductible expenses for U.S. taxes | 1,094,600 | 1,798,200 | -2,781,400 |
Restatement of Prior Year Income, Net of Tax | -25,500 | -91,400 | 321,600 |
Income Tax Reconciliation, Other Adjustments | 0 | -3,822,900 | -384,800 |
Income Tax Reconciliation, Undistributed Foreign Earnings | 0 | 0 | -1,810,300 |
Income Tax Reconciliation, Change in Enacted Tax Rate | 1,075,700 | -1,094,800 | 525,700 |
Deferred Tax Assets, Valuation Allowance | 20,080,000 | 20,581,700 | 18,441,900 |
Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward | 69,047,000 | 43,334,800 | 25,727,700 |
Deferred Tax Assets, Deferred Income | 0 | 10,500 | 23,100 |
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | -7,800 | 13,600 | 15,200 |
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | 9,577,200 | 7,971,900 | 5,466,700 |
Deferred Tax Assets, Goodwill and Intangible Assets | 715,100 | 704,600 | 287,300 |
Deferred Tax Assets, Other | 0 | 0 | -348,700 |
Deferred Tax Assets, Charitable Contribution Carryforwards | 409,800 | 414,900 | 391,800 |
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts | 296,900 | 304,300 | 239,700 |
Deferred Tax Assets, Capital Loss Carryforwards | 6,925,100 | 7,036,800 | 6,644,500 |
Deferred Tax Assets, Tax Credit Carryforwards, Other | 609,700 | 0 | 0 |
Deferred Tax Assets, Net | 87,573,000 | 59,791,400 | 39,144,700 |
Deferred Tax Liabilities Accumulated depreciation | -18,800 | -64,800 | 0 |
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets | -18,176,300 | -4,379,200 | -3,599,100 |
Deferred Tax Liabilities, Gross | 18,195,100 | 4,444,000 | 3,599,100 |
Deferred Tax Assets (Liabilities), Net | 69,377,900 | 55,347,400 | 3,599,100 |
Valuation Allowances and Reserves, Balance | -87,554,100 | -59,726,600 | -39,144,700 |
Deferred Tax Liabilities | ($18,176,200) | ($4,379,200) | ($35,545,600) |
Income_Taxes_Net_Operating_Los
Income Taxes Net Operating Loss Carry Forward (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Net Operating Loss Carry Forward [Abstract] | |||
Income Tax Expense (Benefit) | ($104,202) | $780,104 | ($175,533) |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate | 34.00% |
Discontinued_Operations_Detail
Discontinued Operations (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Regenerative Medicine - China segment [Member] | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Disposal Group, Including Discontinued Operation, Revenue | $52,300 | |
Disposal Group, Including Discontinued Operation, Costs of Goods Sold | 30,600 | |
Disposal Group Including Discontinued Operation Research and Development | 103,300 | |
Disposal Group Including Discontinued Operation Selling General and Administrative | 497,300 | |
Disposal Group, Including Discontinued Operation, Operating Expense | 6,800 | |
Loss on Exit of Segment | 1,138,000 | |
Pharmaceutical Manufacturing - China business [Member] | ||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Disposal Group, Including Discontinued Operation, Revenue | 61,703,100 | |
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents | 8,457,500 | |
Disposal Group, Including Discontinued Operation, Costs of Goods Sold | 40,245,200 | |
Disposal Group Including Discontinued Operation Research and Development | 1,836,400 | |
Disposal Group Including Discontinued Operation Selling General and Administrative | 10,740,000 | |
Disposal Group, Including Discontinued Operation, Operating Expense | $1,045,200 |
Discontinued_Operations_Compan
Discontinued Operations Company recognized loss on exit (Details) (USD $) | 12 Months Ended | 1 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2012 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Loss on exit of segment | $0 | $0 | $30,267,990 | |
Regenerative Medicine - China segment [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Loss on exit of segment | 1,138,000 | |||
Pharmaceutical Manufacturing - China business [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Loss on exit of segment | $3,416,400 | $3,416,400 |
Discontinued_Operations_The_op
Discontinued Operations The operating results of the Regenerative Medicine b China business (Details) (USD $) | 12 Months Ended | 1 Months Ended | |||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2012 | 8-May-14 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | $1,041,000 | ||||
Loss on exit of segment | 0 | 0 | 30,267,990 | ||
Disposal Group, Including Discontinued Operation, Operating Income (Loss) | 0 | 0 | -17,955,344 | ||
Regenerative Medicine - China segment [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Loss on exit of segment | 1,138,000 | ||||
Regenerative Medicine - China segment [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Disposal Group, Including Discontinued Operation, Revenue | 52,300 | ||||
Disposal Group, Including Discontinued Operation, Costs of Goods Sold | -30,600 | ||||
Disposal Group Including Discontinued Operation Research and Development | -103,300 | ||||
Disposal Group Including Discontinued Operation Selling General and Administrative | -497,300 | ||||
Disposal Group, Including Discontinued Operation, Operating Expense | -6,800 | ||||
Loss on Exit of Segment | 1,138,000 | ||||
Disposal Group, Including Discontinued Operation, Operating Income (Loss) | -1,723,700 | ||||
Cash and Cash Equivalents [Member] | Regenerative Medicine - China segment [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Loss on exit of segment | 195,100 | ||||
Gain (Loss) on Disposition of Prepaid Expenses and Other Current Assets [Member] | Regenerative Medicine - China segment [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Loss on exit of segment | 14,900 | ||||
Gain (Loss) on Disposition of Other Assets | -330,500 | ||||
Gain (Loss) on Disposition of Property, Plant and Equipment, Net [Member] | Regenerative Medicine - China segment [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Loss on exit of segment | 1,023,700 | ||||
Gain (Loss) on Disposition of Accounts Payable [Member] | Regenerative Medicine - China segment [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Loss on exit of segment | -177,100 | ||||
Gain (Loss) on Disposition of Accrued Liabilities [Member] | Regenerative Medicine - China segment [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Loss on exit of segment | -79,200 | ||||
Gain (Loss) on Disposition of Accumulated Comprehensive Income [Member] | Regenerative Medicine - China segment [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Loss on exit of segment | ($169,900) |
Discontinued_Operations_The_su
Discontinued Operations The summary of assets and liabilities related to Regenerative Medicine - China business (Details) (USD $) | 12 Months Ended | 1 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2012 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Loss on exit of segment | $0 | $0 | $30,267,990 | |
Assets: | ||||
Assets of Disposal Group, Including Discontinued Operation | 23,800,300 | |||
Regenerative Medicine - China segment [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Loss on exit of segment | $1,138,000 |
Discontinued_Operations_The_op1
Discontinued Operations The operating results of pharmaceutical manufacturing - China business (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Loss on exit of segment | $0 | $0 | ($30,267,990) |
Pharmaceutical Manufacturing - China business [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Disposal Group, Including Discontinued Operation, Revenue | 61,703,100 | ||
Disposal Group, Including Discontinued Operation, Costs of Goods Sold | -40,245,200 | ||
Disposal Group Including Discontinued Operation Research and Development | -1,836,400 | ||
Disposal Group Including Discontinued Operation Selling General and Administrative | -10,740,000 | ||
Disposal Group, Including Discontinued Operation, Operating Expense | -1,045,200 | ||
Loss on exit of segment | ($3,416,400) | ($3,416,400) |
Discontinued_Operations_The_su1
Discontinued Operations The summary of the assets and liabilities related to Pharmaceutical Manufacturing- China discontinued operations (Details) (USD $) | 12 Months Ended | |||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Nov. 13, 2012 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Noncontrolling interests | ($441,047) | ($516,040) | ||
Cash and cash equivalents | 19,174,061 | 46,133,759 | 12,300,000 | |
Total assets | 23,800,300 | |||
Loss on exit of segment | 0 | 0 | -30,267,990 | |
Treasury Stock, Shares | 104,000 | |||
Stock Option Cancelled | 117,000 | |||
Warrants Cancelled | 64,000 | |||
Pharmaceutical Manufacturing - China business [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Available-for-sale Securities | 13,397,900 | |||
Noncontrolling interests | 6,015,000 | |||
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | 4,387,400 | |||
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents | 8,457,500 | |||
Restricted cash | 2,918,100 | |||
Accounts receivable, net | 6,130,200 | |||
Inventory | 15,077,700 | |||
Prepaid expenses and other current assets | 957,800 | |||
Property, plant and equipment, net | 38,102,000 | |||
Other assets | 5,946,300 | |||
Total assets | 27,216,700 | |||
Accounts Payable | -9,604,800 | |||
Accrued liabilities | -2,008,800 | |||
Bank loans | -15,133,500 | |||
Notes payable | -6,599,300 | |||
Unearned revenue | -9,166,800 | |||
Amount due related parties | -7,859,700 | |||
Loss on exit of segment | ($3,416,400) | ($3,416,400) |
Discontinued_Operations_Summar
Discontinued Operations Summary of Operations and Cash Flows of the Pharmaceutical Manufacturing China Business (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Loss on exit of segment | $0 | $0 | ($30,267,990) |
Pharmaceutical Manufacturing - China business [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Disposal Group, Including Discontinued Operation, Revenue | 61,703,100 | ||
Disposal Group, Including Discontinued Operation, Costs of Goods Sold | -40,245,200 | ||
Disposal Group Including Discontinued Operation Research and Development | -1,836,400 | ||
Disposal Group Including Discontinued Operation Selling General and Administrative | -10,740,000 | ||
Disposal Group, Including Discontinued Operation, Operating Expense | -1,045,200 | ||
Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax | -1,794,100 | ||
Disposal Group Including Discontinued Operation Assets Impairment | -31,170,100 | ||
Loss on exit of segment | -3,416,400 | -3,416,400 | |
Disposal Group, Including Discontinued Operation, Operating Income (Loss) | ($28,544,300) |
Related_Party_Transactions_Det
Related Party Transactions (Details) (Equity Purchase Agreement [Member]) | Dec. 31, 2012 | Jun. 18, 2012 |
CBH Acquisition LLC [Member] | ||
Related Party Transaction [Line Items] | ||
Equity Method Investment, Ownership Percentage | 51.00% | |
EET and Fullbright [Member] | ||
Related Party Transaction [Line Items] | ||
Noncontrolling Interest, Ownership Percentage by Parent | 49.00% |
Commitments_and_Contingencies_1
Commitments and Contingencies (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Commitments and Contingencies [Abstract] | |||
Operating Leases, Future Minimum Payments, Next Rolling Twelve Months | $1,567,900 | ||
Operating Leases, Future Minimum Payments Due [Abstract] | |||
2013 | 1,656,900 | ||
2014 | 1,367,300 | ||
2015 | 535,200 | ||
2016 | 492,400 | ||
Thereafter | 628,100 | ||
Total minimum lease payments | 6,247,800 | ||
Operating Leases, Rent Expense | $1,300,000 | $1,100,000 | $1,500,000 |
Subsequent_Events_Details
Subsequent Events (Details) (USD $) | 12 Months Ended | 3 Months Ended | |||||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2015 | 8-May-14 | Mar. 31, 2014 | Feb. 28, 2013 | |
Subsequent Event [Line Items] | |||||||
Common Stock, Shares, Issued | 5,329,593 | ||||||
Proceeds from issuance of common stock | $16,710,645 | $58,736,166 | $16,428,827 | ||||
Proceeds from exercise of warrants | 1,720,725 | 3,028,241 | 6,604,418 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 3,543,456 | ||||||
Proceeds from exercise of options | 271,008 | 150,658 | 0 | ||||
Lease Agreements [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Deferred Rent Credit | 580,000 | ||||||
Security Deposit | 115,000 | ||||||
Aspire Capital Purchase Agreement [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Common Stock, Shares, Issued | 150,000 | 1,600,000 | |||||
Aspire Capital Purchase Agreement [Member] | Common Stock [Member] | |||||||
Subsequent Event [Line Items] | |||||||
Common Stock, Shares, Issued | 1,200,000 | ||||||
Proceeds from issuance of common stock | $4,400,000 |
Quarterly_Financial_Data_Detai
Quarterly Financial Data (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Quarterly Financial Information Disclosure [Abstract] | |||||||||||
Revenues | $5,276 | $4,118 | $4,489 | $4,056 | $4,078 | $3,707 | $4,359 | $2,524 | $17,938,790 | $14,668,455 | $14,329,889 |
Operating Costs and Expenses | 20,830 | 20,376 | 16,919 | 17,555 | 14,573 | 13,020 | 12,530 | 11,355 | |||
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest | -11,691 | -17,177 | -12,769 | -13,830 | -12,719 | -9,277 | -8,626 | -8,864 | |||
Net Income (Loss) Attributable to Parent | ($11,612) | ($16,974) | ($12,605) | ($13,682) | ($12,535) | ($9,071) | ($8,575) | ($8,801) | ($54,872,933) | ($38,981,244) | ($53,769,484) |
NeoStem, Inc. common stockholders | ($0.32) | ($0.48) | ($0.40) | ($0.49) | ($0.47) | ($0.45) | ($0.46) | ($0.53) | ($1.68) | ($1.90) | ($4) |